MEDICINE’S CATEGORIES

Pathology

Cardiology

. Clinical Immunology/Allergy

. Dermatology

. Endocrinology and Metabolism

. Gastroenterology

. General Internal Medicine

. General/Clinical Pathology

. Geriatric Medicine

. Hematology

. Medical Biochemistry

. Medical Genetics

. Medical Microbiology and Infectious Diseases

. Medical Oncology

. Nephrology

. Neurology

. Nuclear Medicine

. Obstetrics/Gynecology

. Occupational Medicine

. Ophthalmology

. Otolaryngology

. Pediatrics

Psychiatry

. Public Health and Preventive Medicine (PhPm)

. Oncology

. Respirology

. Rheumatology

. Urology

Skin & Hair care .

.Herbal drugs

.Urology

.Digestion

.API’S

Active Pharmaceutical Ingredients ( GENERIC’S )

Albuterol (Bronchodilator)
Alprazolam (Tranquilizer)
Ambroxol HCl (Expectorant)
Amiloride HCl (Diuretic)
Amiodarone HCl (Anti-arrhythmic)
Amphetamine Aspartate (CNS, ADHD)§
d-Amphetamine Saccharate (CNS, ADHD)§
Amphetamine Sulfate (CNS, ADHD)§
d-Amphetamine Sulfate (CNS, ADHD)§
Aripiprazole (Neuroleptic)
Benzoyl Peroxide (Keratolytic)
Bisacodyl (Laxative)
Bromazepam (Tranquilizer)
Brotizolam (Hypnotic)
Bupivacaine Base (Local anesthetic)
Bupivacaine HCl (Local anesthetic)
Buprenorphine HCI (Analgesic)§
Chlordiazepoxide Base (Tranquilizer)
Chlordiazepoxide HCl (Tranquilizer)
Chlormadinone Acetate (Progestogen anti-neoplastic)
Chlorothiazide (Diuretic)
Cinacalcet (Antiparathyroid products)
Clobazam (Anxiolytic, anti-convulsant)
Clonazepam (Anti-epileptic)
Clorazepate Dipotassium (Anti-depressant)
Clozapine (Neuroleptic)
Cromolyn Sodium (Anti-allergic)
Diazepam (Tranquilizer)
Diltiazem HCl (Coronary vasodilator)
Dronedarone HCl (Anti-arrhythmic)
Eletriptan (Antimigraine triptan)
Emtricitabine (HIV anti-virals)
Epinephrine (Adrenergic agonist)
Epinephrine Tartrate (Adrenergic agonist)
Erythromycine Lactobionate (Anti-infective)
Estazolam (Hypnotic)
Etizolam (Anxiolytic)
Fentanyl (Analgesic)§
Fentanyl Citrate (Analgesic)§
Flunitrazepam (Hypnotic)
Flurazepam Dihydrochloride (Hypnotic)
Flurazepam HCl (Hypnotic)
Glipizide (Hypoglycemic)
Glyburide/Glibenclamide (Hypoglycemic)
Active Pharmaceutical Ingredients
Hydrochlorothiazide (Diuretic)
Hydrocodone Bitartrate Hydrate (Analgesic)§
Hydromorphone HCl (Analgesic)§
Labetalol HCl (Beta-adrenergic)
Levo Albuterol (Bronchodilator)
Lidocaine Base (Local anesthetic)
Lidocaine HCl (Local anesthetic)
Lorazepam (Anti-anxiety)
Lormetazepam (Hypnotic)
Medazepam (Tranquilizer)
Mesalamine/Mesalazine (Inflammatory bowel disease)
Metaproterenol Sulfate (Bronchodilator)
Midazolam Base (Hypnotic)
Midazolam HCl (Hypnotic)
Midazolam Maleate (Hypnotic)
Nicotine Polacrilex (Smoking cessation aid)
Nitroglycerine Solution (Cardiovasculars)
Norepinephrine Bitartrate (Sympathomimetic agent)
Ondansetron HCl (Anti-emetics)
Oxazepam (Tranquilizer)
Picosulfate Sodium (Laxative)
Potassium p-Aminobenzoate (Therapeutic agent
used in systemic antifibrosis treatment)
Prazepam (Anxiolytic, anticonvulsant)
Raloxifene HCl (Anti-osteoporotic)
Rivastigmine (Alzheimer disease)
Rivastigmine Hydrogen Tartrate (Alzheimer disease)
Salbutamol Sulfate (Bronchodilator)
Sotalol HCl (Beta-adrenoreceptor antagonists)
Sulfasalazine USP (Inflammatory bowel disease)
Temazepam (Tranquilizer)
Teprenone (Anti-ulcer)
Terbutaline Sulfate (Anti-asthmatic)
Terpin Hydrate (Expectorant)
Triazolam (Hypnotic)
Zolpidem Tartrate (Sedative/Hypnotic)
Nitrophthalic Acids and Dervatives
5-Nitroisophthalic acid (5-NIPA)
5-Nitroisophthalic acid monomethyl ester (5-NIPA-MME)
5-Nitroisophthalic acid monoethyl ester (5-NIPA-MEE)
5-Amino-isophthalic acid (5-AIPA)
Pyridine Derivatives
Isocinchomeronic acid (ICA) ***
Miscellaneous
Mucic acid (Galactaric acid) ***
Sodium p-sulfophenyl methallyl ether (SPME)
Sodium p-phenolsulfonate (Technical grade only)
*** Available upon request
This list is not to be construed as a representation of non-infringement or as an offer to sell in those countries
where such would constitute an infringement of third parties’ patent rights.
Chiral Intermediates
(R) 4-Cyano- -methylbenzylamine **
(S) 4-Cyano- -methylbenzylamine **
(R) (+) 2-Amino-5-phenylpentane HCl **
(S) (-) 2-Amino-5-phenylpentane HCl

List of Essential Medicines

Found 1188 recommendations for 591 medicines and 124 therapeutic equivalents

Removed recommendations and rejected applications are shown.

1. Abacavir  

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Abemaciclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

1. Abiraterone

Section

Hormones and antihormones

1. • Oral > Solid: 250 mg; 500 mg

Indications

Malignant neoplasms of prostate

1. Acetazolamide

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

1. • Oral > Solid: 250 mg

Indications

Primary open-angle glaucoma

1. Acetic acid

Section

Ear, nose and throat medicines [c]

1. • Local > Otological > drops: 2% in alcohol

Indications

Infectious diseases of external ear

1. Acetylcysteine

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
   • Oral > Liquid: 10%; 20%

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs Acute or subacute hepatic failure

1. Acetylsalicylic acid

Section

Antimigraine medicines > For treatment of acute attack

1. • Oral > Solid: 300 to 500 mg

Indications

Migraine

Anti-platelet medicines

1. • Oral > Solid: 100 mg

Acute myocardial infarction Cerebral ischaemic stroke

Juvenile joint diseases

1. • Oral > Solid: 100 to 500 mg
   • Local > Rectal > Suppository: 50 to 150 mg

Acute rheumatic fever without mention of heart involvement Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)

1. • Oral > Solid: 100 to 500 mg
   • Local > Rectal > Suppository: 50 to 150 mg

Pain

1. Aciclovir

Section

List of Essential Medicines

Antiherpes medicines

1. • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
   • Oral > Liquid: 200 mg per 5 mL
   • Oral > Solid: 200 mg tablet

Indications

Zoster Varicella Herpes simplex infections

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Ointment: 3% w/w

Herpes simplex keratitis

1. Aclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

1. Activated charcoal

Section

Antidotes and other substances used in poisonings > Non-specific

1. • Oral > Other: powder

Indications

Unspecified injury, poisoning or certain other consequences of external causes

1. Adalimumab

Section

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL

Indications

Axial spondyloarthritis Crohn disease site Juvenile idiopathic arthritis Rheumatoid arthritis

1. Afatinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

1. Albendazole

Section

Antifilarials

1. • Oral > Solid: 400 mg tablet (chewable)

Indications

Filariasis

Intestinal anthelminthics

1. • Oral > Solid: 400 mg tablet (chewable)

Echinococcosis Ascariasis Enterobiasis Trichuriasis Hookworm diseases Cysticercosis

Cysticidal medicines

1. • Oral > Solid: 400 mg tablet (chewable)

Other specified echinococcosis Cysticercosis of central nervous system

1. Alcohol based hand rub

Section

Disinfectants

1. • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol

Indications

Denatured alcohol

1. Alcuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)

Indications

Muscle relaxants

1. All-trans retinoic acid

Section

Targeted therapies

1. • Oral > Solid: 10 mg capsule

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

1. Allopurinol

Section

Medicines used to treat gout

1. • Oral > Solid: 100 mg

Indications

Gout

Supportive medicines

1. • Oral > Solid: 100 mg; 300 mg

Tumour lysis syndrome

1. Alteplase

Section

Thrombolytic medicines

1. • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Cerebral ischaemic stroke

1. Amidotrizoate

Section

Diagnostic agents > Radiocontrast media

1. • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

Indications

Amidotrizoate

1. Amikacin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)

Second choice

co-prescribed with cloxacillin Sepsis without septic shock

Ophthalmological preparations > Anti-infective agents

Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis

Antituberculosis medicines

1. • Parenteral > General injections > unspecified: 100 mg per 2 mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

Multi-drug resistant Mycobacterium tuberculosis

1. Amiloride

Section

Diuretics

1. • Oral > Solid: 5 mg (hydrochloride)

Indications

Oedema Ascites

1. Amiodarone

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
   • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Cardiac arrhythmia

1. Amitriptyline

Section

Medicines for other common symptoms in palliative care

1. • Oral > Solid: 25 mg; 10 mg; 75 mg

Indications

Palliative care

Medicines used in depressive disorders

1. • Oral > Solid: 25 mg; 75 mg

Depressive disorders

1. Amlodipine

Section

Antihypertensive medicines

1. • Oral > Solid: 5 mg (as maleate, mesylate or besylate)

Indications

Essential hypertension

1. Amodiaquine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)

Indications

Malaria due to Plasmodium falciparum

1. Amodiaquine + sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For chemoprevention

1. • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package

Indications

Malaria

1. Amoxicillin

Section

Access group antibiotics

1. • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
   • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
   • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
   • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
   • Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
   • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

First choice

Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia – mild to moderate) Acute sinusitis Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Periapical abscess without sinus Acute pharyngitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia – severe) [children]

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site Infectious cystitis

1. Amoxicillin + clavulanic acid

Section

Access group antibiotics

1. • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
   • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
   • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
   • Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
   • Oral > Solid: 500 mg + 125 mg tablet
   • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

First choice

Bacterial pneumonia (Community-acquired pneumonia – severe) [children] Peritonitis (mild-moderate) Peritoneal abscess (mild-moderate) Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (low-risk) Infectious cystitis Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Chronic obstructive pulmonary disease with acute exacerbation

Second choice

Bacterial pneumonia (Community-acquired pneumonia – mild to moderate) Other specified prophylactic measures Acute otitis media Bacterial infection of joint Osteomyelitis or osteitis co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia – severe)

Other indications

Bacterial infection of unspecified site

Antituberculosis medicines

1. • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
   • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Multi-drug resistant Mycobacterium tuberculosis

1. Amphotericin B

Section

Antifungal medicines

1. • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)

Indications

Blastomycosis Aspergillosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis

Antileishmaniasis medicines

1. • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)

Visceral leishmaniasis

1. Ampicillin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
   • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
   • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

First choice

co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

1. Anakinra

Section

Juvenile joint diseases

1. • Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

1. Anastrozole

Section

Hormones and antihormones

1. • Oral > Solid: 1 mg tablet

Indications

Other specified malignant neoplasms of breast Malignant neoplasms of breast

1. Anidulafungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for Systemic or invasive candidosis

1. Anti-d immunoglobulin

Section

Human immunoglobulins

1. • Parenteral > General injections > IV: 250 µg in single-dose vial
   • Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

Maternal care for red cell antibodies Rh incompatibility reaction

1. Anti-rabies immunoglobulin

Section

Human immunoglobulins

1. • Parenteral > General injections > IM: 150 IU per mL in vial
   • Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

Rabies

1. Anti-rabies virus monoclonal antibodies

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

Indications

Rabies

1. Anti-tetanus immunoglobulin

Section

Human immunoglobulins

1. • Parenteral > General injections > IM: 500 IU in vial

Indications

Tetanus

1. Antirabies hyperimmune serum

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule

Indications

Rabies

1. Antivenom immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Antivenom sera

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > General injections > IV:

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Apixaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

1. Aprepitant

Section

Antiemetic medicines

1. • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
   • Oral > Solid: 80 mg; 125 mg; 165 mg

Indications

Nausea or vomiting

1. Arsenic trioxide

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

1. Artemether

Section

Antimalarial medicines > For curative treatment

1. • Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection)

Indications

Malaria due to Plasmodium falciparum

1. Artemether + lumefantrine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet

Indications

Malaria due to Plasmodium falciparum

1. Artesunate

Section

Antimalarial medicines > For curative treatment

1. • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
   • Oral > Solid: 50 mg tablet
   • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules

Indications

Malaria due to Plasmodium falciparum

1. Artesunate + amodiaquine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet

Indications

Malaria due to Plasmodium falciparum

1. Artesunate + mefloquine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet

Indications

Malaria due to Plasmodium falciparum

1. Artesunate + pyronaridine tetraphosphate

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules

Indications

Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

1. Ascorbic acid

Section

Vitamins and minerals

1. • Oral > Solid: 50 mg

Indications

Scurvy

1. Asparaginase

Section

Cytotoxic medicines

1. • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
   • Powder for injection: 10 000 IU in vial.

Indications

Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites

1. Atazanavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Atenolol

Section

Antianginal medicines

1. • Oral > Solid: 50 mg; 100 mg

Indications

Angina pectoris

Antihypertensive medicines

1. • Oral > Solid: 50 mg; 100 mg

Essential hypertension Therapeutic equivalent to bisoprolol for Essential hypertension

1. Atezolizumab

Section

Immunomodulators

1. • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung

1. Atorvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis

1. Atracurium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 10 mg per mL (besylate)

Indications

Muscle relaxants

1. Atropine

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)

Indications

Exposure to or harmful effects of undetermined intent of pesticides

Preoperative medication and sedation for short-term procedures

1. • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)

Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Diagnostic agents > Ophthalmic medicines

Therapeutic equivalent to tropicamide for Cycloplegic drug

Ophthalmological preparations > Mydriatics

1. • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)

Anterior uveitis

1. Azacitidine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

1. Azathioprine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 50 mg

Indications

Rheumatoid arthritis, serology unspecified Psoriatic arthritis

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
   • Oral > Solid: 50 mg

Failure or rejection of transplanted organs or tissues Relapsing-remitting multiple sclerosis

1. Azithromycin

Section

Watch group antibiotics

1. • Oral > Liquid: 200 mg per 5 mL oral liquid
   • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule

Indications

First choice

Yaws Cholera Trachoma Chlamydia trachomatis Paratyphoid fever Typhoid fever Cholera [children] co-prescribed with ceftriaxone Gonococcal infection

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Trachoma

1. Aztreonam

Section

Reserve group antibiotics

1. • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

1. Barium sulfate

Section

Diagnostic agents > Radiocontrast media

1. • Oral > Liquid: Aqueous suspension

Indications

Barium sulfate with suspending agents

1. Bcg vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tuberculosis

1. Beclometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

Indications

Therapeutic equivalent to budesonide for Asthma Asthma

1. Beclometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for Asthma

1. Bedaquiline

Section

Antituberculosis medicines

1. • Oral > Solid: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Bendamustine

Section

Cytotoxic medicines

1. • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

1. Benzathine benzylpenicillin

Section

Access group antibiotics

1. • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)

Indications

First choice

Syphilis Congenital syphilis [children]

Other indications

Bacterial infection of unspecified site

1. Benznidazole

Section

American trypanosomiasis

1. • Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet

Indications

Chagas disease

1. Benzoic acid + salicylic acid

Section

Dermatological medicines (topical) > Antifungal medicines

1. • Local > Topical > Cream: 6% + 3%
   • Local > Topical > Ointment: 6% + 3%

Indications

Fungal infection of the skin

1. Benzoyl peroxide

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Cream: 5%
   • Local > Topical > Lotion: 5%

Indications

Acne

1. Benzyl benzoate

Section

Dermatological medicines (topical) > Scabicides and pediculicides

1. • Local > Topical > Lotion: 25%

Indications

Pthiriasis Pediculosis corporis Pediculosis capitis Scabies

1. Benzylpenicillin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
   • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

First choice

Congenital syphilis [children] Syphilis co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with gentamicin Sepsis without septic shock

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

1. Betamethasone

Section

Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines

1. • Local > Topical > Cream: 0.1% (as valerate)
   • Local > Topical > Ointment: 0.1% (as valerate)

Indications

Pruritus due to skin disorder Psoriasis of unspecified type Dermatitis or eczema Lichen planus

1. Bevacizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

1. • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

Age related macular degeneration

1. Bicalutamide

Section

Hormones and antihormones

1. • Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

1. Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for Other specified melanoma of skin

1. Biperiden

Section

Antiparkinsonism medicines

1. • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
   • Oral > Solid: 2 mg tablet (hydrochloride)

Indications

Parkinson disease

1. Bisacodyl

Section

Laxatives

Indications

Therapeutic equivalent to senna for Constipation

1. Bisoprolol

Section

Antianginal medicines

1. • Oral > Solid: 1.25 mg; 5 mg

Indications

Angina pectoris

Medicines used in heart failure

1. • Oral > Solid: 1.25 mg; 5 mg

Heart failure

Antiarrhythmic medicines

1. • Oral > Solid: 1.25 mg; 5 mg

Cardiac arrhythmia

Antihypertensive medicines

1. • Oral > Solid: 1.25 mg; 5 mg

Essential hypertension

1. Bleomycin

Section

Cytotoxic medicines

1. • Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)

Indications

Germ cell tumour of testis Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma Other specified malignant neoplasms of the ovary Kaposi sarcoma of unspecified primary site

1. Bortezomib

Section

Targeted therapies

1. • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

1. Bromocriptine

Section

Antiparkinsonism medicines

1. • Oral > Solid: 2.5 mg; 5 mg

Indications

Parkinson disease

1. Budesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose

Indications

Asthma

Ear, nose and throat medicines [c]

1. • Local > Nasal > Spray: 100 µg per dose

Allergic rhinitis

1. Budesonide + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose

Indications

Asthma

1. Budesonide + salmeterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for Asthma

1. Bumetanide

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to furosemide for Heart failure

Diuretics

Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema

1. Bupivacaine

Section

Local anaesthetics

1. • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
   • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)

Indications

Local anaesthetics

1. Buprenorphine

Section

Medicines for disorders due to psychoactive substance use

Indications

Therapeutic equivalent to methadone for Opioid dependence

1. Bupropion

Section

Medicines for disorders due to psychoactive substance use

1. • Oral > Solid: 150 mg sustained-release (hydrochloride)

Indications

Nicotine dependence

1. C1 esterase inhibitor

Section

Plasma-derived medicines

1. • Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

Hereditary angioedema

1. Cabergoline

Section

Antiparkinsonism medicines

1. • Oral > Solid: 0.5 mg

Indications

Parkinson disease

1. Caffeine citrate

Section

Medicines administered to the neonate [c]

1. • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
   • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

Apnoea of newborn

1. Calamine

Section

Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines

1. • Local > Topical > Lotion:

Indications

Pruritus

1. Calcipotriol

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Cream: 50 µg per mL (0.005%)
   • Local > Topical > Lotion: 50 µg per mL (0.005%)
   • Local > Topical > Ointment: 50 µg per mL (0.005%)

Indications

Psoriasis of unspecified type

1. Calcitriol

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type

1. Calcium

Section

Vitamins and minerals

1. • Oral > Solid: 500 mg (elemental calcium)

Indications

Calcium deficiency

1. Calcium folinate

Section

Cytotoxic medicines

1. • Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet
   • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
   • Oral > Solid: 15 mg tablet

Indications

Malignant neoplasm metastasis in large intestine Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone and articular cartilage of unspecified sites Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon Malignant trophoblastic neoplasms of placenta

1. Calcium gluconate

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Hypermagnesaemia

Vitamins and minerals

1. • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Tetany due to acute calcium deficiency

1. Canagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

1. Capecitabine

Section

Cytotoxic medicines

1. • Oral > Solid: 150 mg tablet; 500 mg tablet

Indications

Malignant neoplasms of colon Other specified malignant neoplasms of breast Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum

1. Capreomycin

Section

Antituberculosis medicines

1. • Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Captopril

Section

Medicines used in heart failure

1. • Oral > Solid: 25 mg

Indications

Heart failure

1. Carbachol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Indications

Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma Therapeutic equivalent to pilocarpine for Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine for Ocular hypertension

1. Carbamazepine

Section

Anticonvulsants/antiepileptics

1. • Oral > Liquid: 100 mg per 5 mL
   • Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)

Indications

Epilepsy or seizures

Medicines used in bipolar disorders

1. • Oral > Solid: 100 mg scored; 200 mg scored

Bipolar or related disorders

1. Carbetocin

Section

Uterotonics

1. • Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

1. Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to methimazole for Thyrotoxicosis

1. Carboplatin

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain Osteosarcoma of bone and articular cartilage of unspecified sites Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis

1. Carvedilol

Section

Antianginal medicines

Indications

Therapeutic equivalent to bisoprolol for Angina pectoris

Medicines used in heart failure

Therapeutic equivalent to bisoprolol for Heart failure

Antiarrhythmic medicines

Therapeutic equivalent to bisoprolol for Cardiac arrhythmia

Antihypertensive medicines

Therapeutic equivalent to bisoprolol for Essential hypertension

1. Caspofungin

Section

Antifungal medicines

Indications

Therapeutic equivalent to micafungin for Systemic or invasive candidosis

1. Cefalexin

Section

Access group antibiotics

1. • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
   • Oral > Solid: 250 mg (as monohydrate)
   • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

1. Cefazolin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

First choice

Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures

Second choice

Osteomyelitis or osteitis Bacterial infection of joint

Other indications

Surgical site infection

1. Cefepime

Section

Watch group antibiotics

1. • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

1. Cefiderocol

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 1 g in vial (as sulfate toxylate) powder for injection

Indications

Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

1. Cefixime

Section

Watch group antibiotics

1. • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
   • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection

1. Cefotaxime

Section

Watch group antibiotics

1. • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia – severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate)

Second choice

Acute pyelonephritis (mild to moderate) Inflammatory and other diseases of prostate (mild to moderate) Sepsis without septic shock Osteomyelitis or osteitis Bacterial infection of joint

Other indications

Bacterial infection of unspecified site

1. Ceftaroline

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

1. Ceftazidime

Section

Watch group antibiotics

1. • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

First choice

co-prescribed with vancomycin Endophthalmitis

Other indications

Pseudomonas aeruginosa resistant to other antibiotic

1. Ceftazidime + avibactam

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

1. Ceftolozane + tazobactam

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

Carbapenem-resistant Pseudomonas aeruginosa

1. Ceftriaxone

Section

Watch group antibiotics

1. • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
   • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
   • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

First choice

Other specified pneumonia (Hospital-acquired pneumonia) Bacterial pneumonia (Community-acquired pneumonia – severe) [children] Paratyphoid fever Bacterial meningitis Typhoid fever co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia – severe) co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with vancomycin Endophthalmitis

Second choice

Acute pyelonephritis (mild to moderate) Inflammatory and other diseases of prostate (mild to moderate) Osteomyelitis or osteitis Bacterial infection of joint Infectious gastroenteritis or colitis without specification of infectious agent Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

1. Cefuroxime

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choice

Other specified prophylactic measures

1. Certolizumab pegol

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis

1. Cetirizine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type

1. Chlorambucil

Section

Cytotoxic medicines

1. • Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Chronic lymphocytic leukaemia or small lymphocytic lymphoma

1. Chloramphenicol

Section

Access group antibiotics

1. • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
   • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
   • Oral > Liquid: 150 mg per 5 mL (as palmitate)
   • Oral > Solid: 250 mg capsule

Indications

Second choice

Bacterial meningitis

Other indications

Bacterial infection of unspecified site

1. Chlorhexidine

Section

Medicines administered to the neonate [c]

1. • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
   • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Indications

Omphalitis of newborn

Antiseptics

1. • Local > Topical > Solution: 5% (digluconate) for dilution

Chlorhexidine

1. Chlorine base compound

Section

Disinfectants

1. • Local > Topical > Powder: 0.1% available chlorine for solution
   • Local > Topical > Liquid: 0.1% available chlorine for solution
   • Local > Topical > Solid: 0.1% available chlorine for solution

Indications

Disinfectant, not elsewhere classified

1. Chloroquine

Section

Antimalarial medicines > For chemoprevention

1. • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
   • Oral > Solid: 150 mg tablet (as phosphate or sulfate)

Indications

Malaria due to Plasmodium falciparum Malaria due to Plasmodium ovale Malaria due to Plasmodium vivax Malaria due to Plasmodium malariae

Antimalarial medicines > For curative treatment

1. • Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
   • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
   • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

Rheumatoid arthritis

1. Chlorothiazide

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to hydrochlorothiazide for Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to hydrochlorothiazide for Heart failure

1. Chloroxylenol

Section

Disinfectants

1. • Local > Topical > Solution: 4.8%

Indications

Phenol disinfectant, not elsewhere classified

1. Chlorpromazine

Section

Medicines used in psychotic disorders

1. • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
   • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
   • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Schizophrenia or other primary psychotic disorders

1. Chlortalidone

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to hydrochlorothiazide for Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to hydrochlorothiazide for Heart failure

1. Chlortetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Trachoma Therapeutic equivalent to tetracycline for Infectious blepharitis

1. Cholera vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against cholera alone

1. Ciclesonide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for Asthma

1. Ciclosporin

Section

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
   • Oral > Solid: 25 mg

Indications

Failure or rejection of transplanted organs or tissues

1. Cimetidine

Section

Antiulcer medicines

1. • Oral > Solid: 200 mg
   • Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

Indications

Gastro-oesophageal reflux disease Peptic ulcer, site unspecified

1. Ciprofloxacin

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
   • Oral > Liquid: 250 mg per 5 mL (anhydrous)
   • Oral > Solid: 250 mg (as hydrochloride)
   • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

First choice

Acute pyelonephritis (mild to moderate) Typhoid fever Inflammatory and other diseases of prostate (mild to moderate) Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Neutropenia (low-risk)

Second choice

Cholera [children] Cholera co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Ear, nose and throat medicines [c]

1. • Local > Otological > drops: 0.3% (as hydrochloride)

Infectious diseases of external ear

1. Cisplatin

Section

Cytotoxic medicines

1. • Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
   • Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant neoplasms of nasopharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx

1. Citalopram

Section

Medicines used in depressive disorders

Indications

Therapeutic equivalent to fluoxetine for Depressive disorders

1. Clarithromycin

Section

Watch group antibiotics

1. • Oral > Solid: 500 mg
   • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
   • Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

First choice

co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia – severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia – severe)

Second choice

Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia – severe)

Other indications

Helicobacter pylori associated gastric ulcer

1. Clindamycin

Section

Access group antibiotics

1. • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
   • Oral > Solid: 150 mg (as hydrochloride) capsule
   • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
   • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
   • Oral > Solid: 150 mg (as hydrochloride)

Indications

First choice

co-prescribed with piperacillin + tazobactam Necrotising fasciitis

Second choice

Osteomyelitis or osteitis Bacterial infection of joint

Other indications

Bacterial infection of unspecified site

1. Clofazimine

Section

Antituberculosis medicines

1. • Oral > Solid: 100 mg; 50 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Antileprosy medicines

1. • Oral > Solid: 100 mg; 50 mg

Leprosy

1. Clomifene

Section

Ovulation inducers

1. • Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

1. Clomipramine

Section

Medicines used for obsessive compulsive disorders

1. • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Obsessive-compulsive disorder

1. Clonazepam

Section

Anticonvulsants/antiepileptics

1. • Oral > Solid: 500 µg

Indications

Generalised myoclonic seizure

1. Clopidogrel

Section

Anti-platelet medicines

1. • Oral > Solid: 75 mg; 300 mg

Indications

Acute ischaemic heart disease Presence of coronary angioplasty implant or graft

1. Clotrimazole

Section

Antifungal medicines

1. • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

Indications

Vulvovaginal candidosis

1. Cloxacillin

Section

Access group antibiotics

1. • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
   • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
   • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis Osteomyelitis or osteitis Bacterial infection of joint

Second choice

co-prescribed with amikacin Sepsis without septic shock

Other indications

Bacterial infection of unspecified site

1. Clozapine

Section

Medicines used in psychotic disorders

1. • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

Indications

Schizophrenia or other primary psychotic disorders

1. Coagulation factor IX complex

Section

Blood coagulation factors

1. • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B

1. Coagulation factor VIII

Section

Blood coagulation factors

1. • Parenteral > General injections > IV: 500 IU in vial powder for injection

Indications

Haemophilia A

1. Coal tar

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Solution: 5%

Indications

Psoriasis of unspecified type

1. Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for Other specified melanoma of skin

1. Codeine

Section

Opioid analgesics

1. • Oral > Solid: 30 mg tablet (codeine phosphate)

Indications

Pain

Antitussives

1. • Oral > Solid: 10 mg tablet (codeine phosphate)

Cough

Medicines for diarrhoea

1. • Oral > Solid: 30 mg tablet (codeine phosphate)

Diarrhoea

1. Colchicine

Section

Medicines used to treat gout

1. • Oral > Solid: 0.5 mg

Indications

Gout

1. Colecalciferol

Section

Vitamins and minerals

1. • Oral > Liquid: 400 IU per mL
   • Oral > Solid: 400 IU; 1000 IU

Indications

Calcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency

1. Colistin (injection)

Section

Reserve group antibiotics

1. • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)

Indications

Other specified bacterial diseases Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

1. Compound sodium lactate solution

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: injectable solution

Indications

Other specified disorders of fluid, electrolyte or acid-base balance Hypovolaemic shock

1. Condoms

Section

Barrier methods

1. • –

Indications

Contact with health services for contraceptive management

1. Copper-containing intrauterine device

Section

Intrauterine devices

1. • –

Indications

Contact with health services for insertion of contraceptive device

1. Crizotinib

Section

Targeted therapies

1. • Oral > Solid: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

1. Cyanocobalamin

Section

Antianaemia medicines

1. • .

Indications

Anaemias or other erythrocyte disorders

1. Cyclizine

Section

Medicines for other common symptoms in palliative care

1. • Oral > Solid: 50 mg tablet
   • Parenteral > General injections > unspecified: 50 mg per mL

Indications

Palliative care

1. Cyclopentolate

Section

Diagnostic agents > Ophthalmic medicines

Indications

Therapeutic equivalent to tropicamide for Cycloplegic drug

Ophthalmological preparations > Mydriatics

Therapeutic equivalent to atropine for Anterior uveitis

1. Cyclophosphamide

Section

Cytotoxic medicines

1. • Oral > Solid: 25 mg tablet
   • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
   • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
   • Oral > Solid: 25 mg tablet; 50 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified malignant neoplasms of breast Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Rhabdomyosarcoma primary site Hodgkin lymphoma

1. Cycloserine

Section

Antituberculosis medicines

1. • Oral > Solid: 250 mg; 125 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Cytarabine

Section

Cytotoxic medicines

1. • Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Myeloid leukaemia

1. Dabigatran

Section

Medicines affecting coagulation

1. • Oral > Solid: 110 mg; 150 mg

Indications

Venous thromboembolism Other specified atrial fibrillation

1. Dabrafenib

Section

Targeted therapies

1. • Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

1. Dacarbazine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Hodgkin lymphoma

1. Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)

Indications

Chronic hepatitis C

1. Daclatasvir + sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 60 mg + 400 mg

Indications

Chronic hepatitis C

1. Dactinomycin

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites

1. Dalteparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for Venous thromboembolism Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease

1. Dapagliflozin

Section

Oral hypoglycaemic agents

Indications

Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus

1. Dapsone

Section

Antileprosy medicines

1. • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

1. Daptomycin

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

1. Daratumumab

Section

Immunomodulators

1. • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

1. Darbepoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

1. Darunavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Dasabuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

1. Dasatinib

Section

Targeted therapies

1. • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

1. Daunorubicin

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia

1. Deferasirox

Section

Other medicines for haemoglobinopathies

Indications

Therapeutic equivalent to deferoxamine for Other specified sickle cell disorders or other haemoglobinopathies

1. Deferoxamine

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Other medicines for haemoglobinopathies

1. • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Other specified sickle cell disorders or other haemoglobinopathies

1. Delafloxacin

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
   • Oral > Solid: 450 mg

Indications

Methicillin resistant Staphylococcus aureus

1. Delamanid

Section

Antituberculosis medicines

1. • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Dengue vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Desmopressin

Section

Medicines affecting coagulation

1. • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
   • Local > Nasal > Spray: 10 µg per dose (acetate)

Indications

Haemophilia A Von Willebrand disease

1. Dexamethasone

Section

Other medicines administered to the mother

1. • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Hormones and antihormones

1. • Oral > Solid: 4 mg
   • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
   • Oral > Liquid: 2 mg per 5 mL
   • Oral > Solid: 2 mg; 4 mg

Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia

Antiallergics and medicines used in anaphylaxis

1. • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Allergic or hypersensitivity conditions of unspecified type

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 2 mg per 5 mL
   • Oral > Solid: 2 mg; 4 mg
   • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Palliative care

Antiemetic medicines

1. • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
   • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
   • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)

Nausea or vomiting

1. Dextran 40

Section

Plasma substitutes

1. • .

Indications

Hypovolaemia

1. Dextran 70

Section

Plasma substitutes

1. • Parenteral > General injections > IV: 6% injectable solution

Indications

Hypovolaemia

1. Diaphragms

Section

Barrier methods

1. • –

Indications

Contact with health services for contraceptive management

1. Diazepam

Section

Anticonvulsants/antiepileptics

1. • Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
   • Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes

Indications

Status epilepticus Therapeutic equivalent to lorazepam for Status epilepticus

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 2 mg per 5 mL
   • Oral > Solid: 5 mg; 10 mg
   • Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg
   • Parenteral > General injections > unspecified: 5 mg per mL

Palliative care

Medicines for anxiety disorders

1. • Oral > Solid: 5 mg (scored); 2 mg (scored)

Anxiety

1. Diazoxide

Section

Medicines for hypoglycaemia

1. • Oral > Liquid: 50 mg per mL
   • Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

1. Didanosine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
   • Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Diethylcarbamazine

Section

Antifilarials

1. • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

Indications

Lymphatic filariasis

1. Digitoxin

Section

Medicines used in heart failure

1. • Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
   • Oral > Solid: 50 µg; 100 µg

Indications

Heart failure

1. Digoxin

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
   • Oral > Liquid: 50 µg per mL
   • Oral > Solid: 62.5 µg; 250 µg

Indications

Cardiac arrhythmia

Medicines used in heart failure

1. • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
   • Oral > Liquid: 50 µg per mL
   • Oral > Solid: 62.5 µg; 250 µg

Heart failure

1. Dihydroartemisinin + piperaquine phosphate

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet

Indications

Malaria due to Plasmodium falciparum

1. Dihydroergocryptine mesylate

Section

Antiparkinsonism medicines

1. • Oral > Solid:

Indications

Parkinson disease

1. Diloxanide

Section

Antiamoebic and antigiardiasis medicines

1. • Oral > Solid: 500 mg (furoate)

Indications

Amoebiasis

1. Dimercaprol

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Diphtheria antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

Need for immunization against diphtheria alone

1. Diphtheria vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria alone

1. Diphtheria-pertussis-tetanus vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

1. Diphtheria-tetanus vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against combinations of infectious diseases

1. Docetaxel

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate Unspecified malignant neoplasms of ill-defined or unspecified sites

1. Docusate sodium

Section

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 50 mg per 5 mL oral liquid
   • Oral > Solid: 100 mg capsule

Indications

Palliative care

1. Dolasetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to ondansetron for Palliative care

Antiemetic medicines

Therapeutic equivalent to ondansetron for Nausea or vomiting

1. Dolutegravir

Section

Antiretrovirals > Integrase inhibitors

1. • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Dopamine

Section

Medicines used in heart failure

1. • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)

Indications

Heart failure Cardiogenic shock

1. Doxorubicin

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of breast Other specified malignant neoplasms of breast Hodgkin lymphoma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Kaposi sarcoma of unspecified primary site Diffuse large B-cell lymphomas Rhabdomyosarcoma primary site

1. Doxycycline

Section

Access group antibiotics

1. • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
   • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
   • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
   • Oral > Solid: 100 mg (as hyclate)
   • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Indications

First choice

Chlamydia trachomatis Cholera

Second choice

Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation Bacterial pneumonia (Community-acquired pneumonia – mild to moderate)

Other indications

Bacterial infection of unspecified site

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

Malaria due to Plasmodium falciparum

Antimalarial medicines > For chemoprevention

1. • Oral > Solid: 100 mg (hydrochloride or hyclate)

Malaria due to Plasmodium falciparum

1. Durvalumab

Section

Immunomodulators

Indications

Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung

1. Edoxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

1. Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

1. • Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Eflornithine

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

1. • Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride)

Indications

African trypanosomiasis

1. Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

1. Empagliflozin

Section

Oral hypoglycaemic agents

1. • Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

1. Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Liquid: 10 mg per mL
   • Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus

1. Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Enalapril

Section

Antihypertensive medicines

1. • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)

Indications

Essential hypertension

Medicines used in heart failure

1. • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)

Heart failure

1. Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

1. Enoxaparin

Section

Medicines affecting coagulation

1. • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
   • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule

Indications

Venous thromboembolism Acute ischaemic heart disease

1. Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Liquid: 0.05 mg per mL
   • Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

1. Enzalutamide

Section

Hormones and antihormones

1. • Oral > Solid: 40 mg

Indications

Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate

1. Ephedrine

Section

Local anaesthetics

1. • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

Indications

Cardiac complications of anaesthesia during labour or delivery

1. Epinephrine

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

Indications

Cardiac arrest

Ophthalmological preparations > Mydriatics

1. • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

Primary open-angle glaucoma

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

Chronic obstructive pulmonary disease Asthma

Antiallergics and medicines used in anaphylaxis

1. • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

Anaphylaxis

1. Epoetin alfa

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

1. Epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

1. Epoetin theta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

1. Equine rabies immunoglobulin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

Indications

Rabies

1. Eravacycline

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Carbapenem resistant Enterobacterales

1. Ergocalciferol

Section

Vitamins and minerals

1. • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
   • Oral > Solid: 1.25 mg (50 000 IU)

Indications

Therapeutic equivalent to colecalciferol for Calcium deficiency Therapeutic equivalent to colecalciferol for Vitamin D deficiency Calcium deficiency Vitamin D deficiency

1. Ergometrine

Section

Uterotonics

1. • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

Indications

Postpartum haemorrhage

1. Erlotinib

Section

Targeted therapies

1. • Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

1. Erythromycin

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
   • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
   • Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choice

Therapeutic equivalent to clarithromycin for Acute pharyngitis

Other indications

Bacterial infection of unspecified site

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Ointment: 0.5%

Gonococcal infection of eye Chlamydial conjunctivitis

1. Erythropoiesis-stimulating agents

Section

Antianaemia medicines

1. • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

Anaemia due to chronic disease

1. Escitalopram

Section

Medicines used in depressive disorders

Indications

Therapeutic equivalent to fluoxetine for Depressive disorders

1. Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

1. • Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

1. Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis

1. Ethambutol

Section

Antituberculosis medicines

1. • Oral > Liquid: 25 mg per mL
   • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
   • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Indications

Tuberculosis Other specified tuberculosis

1. Ethambutol + isoniazid

Section

Antituberculosis medicines

1. • Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

1. Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

1. • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

1. Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

1. • Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

1. Ethanol

Section

Antiseptics

1. • Local > Topical > Solution: 70% (denatured)

Indications

Denatured alcohol

1. Ether

Section

General anaesthetics and oxygen > Inhalational medicines

1. • Respiratory > Inhalation > solution:

Indications

Anaesthetics and therapeutic gases

1. Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives

1. • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

1. Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives

1. • Oral > Solid: 50 µg + 250 µg [4]
   • Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception Contact with health services for contraceptive management

1. Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

1. • Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

1. Ethionamide

Section

Antituberculosis medicines

1. • Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible)

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Ethosuximide

Section

Anticonvulsants/antiepileptics

1. • Oral > Liquid: 250 mg per 5 mL
   • Oral > Solid: 250 mg

Indications

Absence seizures, typical

1. Etonogestrel-releasing implant

Section

Implantable contraceptives

1. • Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

1. Etoposide

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
   • Oral > Solid: 100 mg capsule
   • Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Hodgkin lymphoma Other specified malignant neoplasms of the ovary Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Retinoblastoma Myeloid leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites

1. Everolimus

Section

Targeted therapies

1. • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)

Indications

Other specified gliomas of brain

1. Fentanyl

Section

Opioid analgesics

1. • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour

Indications

Chronic cancer pain

1. Ferrous salt

Section

Antianaemia medicines

1. • Oral > Liquid: 25 mg per mL iron (as sulfate)
   • Oral > Solid: 60 mg iron

Indications

Iron deficiency anaemia

1. Ferrous salt + folic acid

Section

Antianaemia medicines

1. • Oral > Solid: 60 mg iron + 400 µg tablet
   • Oral > Solid: 60 mg iron + 2.8 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy Iron deficiency anaemia

1. Fexinidazole

Section

Medicines for the treatment of 1st stage African trypanosomiasis

1. • Oral > Solid: 600 mg

Indications

African trypanosomiasis

Medicines for the treatment of 2nd stage African trypanosomiasis

1. • Oral > Solid: 600 mg

African trypanosomiasis

1. Fexofenadine

Section

Antiallergics and medicines used in anaphylaxis

Indications

Therapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type

1. Fifth generation cephalosporins

Section

Reserve group antibiotics

1. • .

Indications

Other specified bacterial diseases

1. Filgrastim

Section

Immunomodulators

1. • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

Acquired neutropaenia

1. Fingolimod

Section

Immunomodulators for non-malignant disease

1. • Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

1. Fluconazole

Section

Antifungal medicines

1. • Parenteral > General injections > IV: 2 mg per mL in vial
   • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 50 mg capsule

Indications

Cryptococcosis Candidosis

1. Flucytosine

Section

Antifungal medicines

1. • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
   • Oral > Solid: 250 mg capsule

Indications

Cryptococcosis

1. Fludarabine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
   • Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

1. Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

1. • Oral > Solid: 100 µg (acetate)

Indications

Adrenocortical insufficiency

1. Flunisolide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for Asthma

1. Fluorescein

Section

Diagnostic agents > Ophthalmic medicines

1. • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

Indications

Fluorescein

1. Fluoride

Section

Dental preparations

1. • Local > Dental > Paste: 1000 to 1500 ppm fluoride (any type)
   • Local > Dental > Cream: 1000 to 1500 ppm fluoride (any type)
   • Local > Dental > Gel: 1000 to 1500 ppm fluoride (any type)
   • Local > Dental > Other: In other appropriate topical formulations

Indications

Dental caries

1. Fluorouracil

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Indications

Malignant neoplasms of breast Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum Malignant neoplasms of colon

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Ointment: 5%

Plantar warts

1. Fluoxetine

Section

Medicines for other common symptoms in palliative care

1. • Oral > Solid: 20 mg (as hydrochloride)

Indications

Palliative care

Medicines used in depressive disorders

1. • Oral > Solid: 20 mg (as hydrochloride)

Depressive disorders

1. Fluphenazine

Section

Medicines used in psychotic disorders

1. • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)

Indications

Schizophrenia or other primary psychotic disorders

1. Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

1. Fluticasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for Asthma

1. Fluticasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for Asthma

1. Fluticasone furoate + vilanterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for Asthma

1. Fluvastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis

1. Fluvoxamine

Section

Medicines used in depressive disorders

Indications

Therapeutic equivalent to fluoxetine for Depressive disorders

1. Folic acid

Section

Antianaemia medicines

1. • Oral > Solid: 1 mg tablet; 5 mg tablet
   • Oral > Solid: 400 µg

Indications

Folate deficiency anaemia Cephalocele Anencephaly or similar anomalies Spina bifida

1. Fomepizole

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Fosfomycin (injection)

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

1. Fourth generation cephalosporins

Section

Watch group antibiotics

1. • .

Indications

Other specified bacterial diseases

1. Fresh-frozen plasma

Section

Blood and blood components

1. • Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

1. Fulvestrant

Section

Hormones and antihormones

1. • Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

1. Furosemide

Section

Medicines used in heart failure

1. • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
   • Oral > Liquid: 20 mg per 5 mL
   • Oral > Solid: 40 mg

Indications

Heart failure

Diuretics

1. • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
   • Oral > Liquid: 20 mg per 5 mL
   • Oral > Solid: 40 mg; 10 mg; 20 mg

Anuria or oliguria Oedema

1. Gabapentin

Section

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)

1. • Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

Indications

Neuropathic pain

1. Gallamine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

Indications

Muscle relaxants

1. Gatifloxacin

Section

Antituberculosis medicines

1. • Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

1. Gemcitabine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

1. Gentamicin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

Neonatal meningitis co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia – severe) [children] co-prescribed with benzylpenicillin Sepsis without septic shock co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children]

Second choice

Other specified prophylactic measures Gonococcal infection

Other indications

Bacterial infection of unspecified site

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

Other specified conjunctivitis Infectious blepharitis

1. Glass ionomer cement

Section

Dental preparations

1. • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

Indications

Dental caries

1. Glatiramer acetate

Section

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Indications

Relapsing-remitting multiple sclerosis

1. Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules

Indications

Chronic hepatitis C

1. Glibenclamide

Section

Oral hypoglycaemic agents

1. • Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

1. Gliclazide

Section

Oral hypoglycaemic agents

1. • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

1. Glucagon

Section

Medicines for hypoglycaemia

1. • Parenteral > General injections > unspecified: 1 mg per mL

Indications

Hypoglycaemia in the context of diabetes

1. Glucose

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
   • Parenteral > General injections > IV: 50% hypertonic

Indications

Other specified disorders of fluid, electrolyte or acid-base balance Hypoglycaemia without associated diabetes

1. Glucose + sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

1. Glutaral

Section

Disinfectants

1. • Local > Topical > Solution: 2%

Indications

Glutaral nonmedicinal

1. Glyceryl trinitrate

Section

Antianginal medicines

1. • Oral > Solid: 500 µg sublingual tablet

Indications

Angina pectoris

1. Glycopyrronium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

1. Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis

1. Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

1. Granisetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to ondansetron for Palliative care

Antiemetic medicines

Therapeutic equivalent to ondansetron for Nausea or vomiting

1. Griseofulvin

Section

Antifungal medicines

1. • Oral > Liquid: 125 mg per 5 mL
   • Oral > Solid: 125 mg; 250 mg

Indications

Dermatophytosis

1. Haemophilus influenzae type b vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

1. Haloperidol

Section

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 2 mg per mL
   • Oral > Solid: 0.5 mg; 2 mg; 5 mg
   • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule

Indications

Palliative care

Medicines used in psychotic disorders

1. • Parenteral > General injections > IM: 5 mg per mL in ampoule
   • Oral > Liquid: 2 mg per mL
   • Oral > Solid: 2 mg; 0.5 mg; 5 mg

Schizophrenia or other primary psychotic disorders

1. Halothane

Section

General anaesthetics and oxygen > Inhalational medicines

1. • Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

1. Heparin sodium

Section

Medicines affecting coagulation

1. • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule

Indications

Acute ischaemic heart disease Unstable angina Venous thromboembolism

1. Hepatitis a vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

1. Hepatitis b vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against viral hepatitis

1. Homatropine

Section

Ophthalmological preparations > Mydriatics

1. • Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

Indications

Anterior uveitis Therapeutic equivalent to atropine for Anterior uveitis

1. Hpv vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Hydralazine

Section

Antihypertensive medicines

1. • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
   • Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
   • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

Indications

Essential hypertension Gestational hypertension

1. Hydrochlorothiazide

Section

Antihypertensive medicines

1. • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 25 mg; 12.5 mg

Indications

Essential hypertension

Medicines used in heart failure

1. • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 25 mg

Heart failure

Diuretics

1. • Oral > Solid: 25 mg

Oedema

1. Hydrocortisone

Section

Hormones and antihormones

1. • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia

Adrenal hormones and synthetic substitutes

1. • Oral > Solid: 5 mg; 10 mg; 20 mg

Adrenocortical insufficiency

Ophthalmological preparations > Anti-inflammatory agents

1. • Local > Ophthalmological > Ointment: 1% (acetate)

Scleritis Anterior uveitis

Antiallergics and medicines used in anaphylaxis

1. • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)

Anaphylaxis

Anti-inflammatory medicines

1. • Local > Rectal > Suppository: 25 mg (acetate)
   • Local > Rectal > Retention enema: 100 mg per 60 mL

Crohn disease site Ulcerative colitis

Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines

1. • Local > Topical > Cream: 1% (acetate)
   • Local > Topical > Ointment: 1% (acetate)

Dermatitis or eczema Pruritus due to skin disorder Psoriasis of unspecified type Lichen planus

1. Hydromorphone

Section

Opioid analgesics

Indications

Therapeutic equivalent to morphine for Pain

1. Hydroxocobalamin

Section

Antianaemia medicines

1. • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

Megaloblastic anaemia due to vitamin B12 deficiency

1. Hydroxycarbamide

Section

Other medicines for haemoglobinopathies

1. • Oral > Solid: 200 mg; 500 mg; 1 g

Indications

Other specified sickle cell disorders or other haemoglobinopathies

Cytotoxic medicines

1. • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

1. Hydroxychloroquine

Section

Antimalarial medicines > For chemoprevention

Indications

Therapeutic equivalent to chloroquine for Malaria due to Plasmodium falciparum

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 200 mg (as sulfate)

Systemic lupus erythematosus Cutaneous lupus erythematosus of unspecified type

1. Hyoscine butylbromide

Section

Medicines for other common symptoms in palliative care

1. • Parenteral > General injections > unspecified: 20 mg per mL injection

Indications

Palliative care

1. Hyoscine hydrobromide

Section

Medicines for other common symptoms in palliative care

1. • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
   • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection

Indications

Palliative care

1. Hypochlorous acid

Section

Antiseptics

1. • Local > Topical > Solution:

Indications

Disinfectant, not elsewhere classified

1. Ibrutinib

Section

Targeted therapies

1. • Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

1. Ibuprofen

Section

Antimigraine medicines > For treatment of acute attack

1. • Oral > Solid: 200 mg; 400 mg

Indications

Migraine

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)

1. • Oral > Liquid: 200 mg per 5 mL
   • Oral > Solid: 200 mg; 400 mg; 600 mg

Pain

Medicines administered to the neonate [c]

1. • Parenteral > General injections > IV: 5 mg per mL

Patent arterial duct

1. Idoxuridine

Section

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Solution (eye drops): 0.1%
   • Local > Ophthalmological > Ointment: 0.2%

Indications

Herpes simplex keratitis

1. Ifosfamide

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
   • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis

1. Imatinib

Section

Targeted therapies

1. • Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Gastrointestinal stromal tumour of unspecified gastrointestinal sites Chronic myeloid leukaemia, not elsewhere classified

1. Imipenem + cilastatin

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

Second choice

Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)

Other indications

Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant Acinetobacter baumannii

Antituberculosis medicines

Therapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosis

1. Indapamide

Section

Antihypertensive medicines

Indications

Therapeutic equivalent to hydrochlorothiazide for Essential hypertension

Medicines used in heart failure

Therapeutic equivalent to hydrochlorothiazide for Heart failure

1. Indinavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to ibuprofen for Patent arterial duct

1. Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis

1. Influenza vaccine (seasonal)

Section

Recommendations for immunization programmes with certain characteristics

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against influenza

1. Insulin

Section

Insulins

1. • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)

Indications

Type 1 diabetes mellitus Type 2 diabetes mellitus

1. Insulin analogues

Section

Insulins

1. • Not specified

Indications

Type 1 diabetes mellitus Type 2 diabetes mellitus

1. Insulin degludec

Section

Insulins

1. • Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus

1. Insulin detemir

Section

Insulins

Indications

Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus

1. Insulin glargine

Section

Insulins

1. • Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus

1. Intermediate-acting insulin

Section

Insulins

1. • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin

Indications

Type 2 diabetes mellitus Type 1 diabetes mellitus

1. Intraperitoneal dialysis solution

Section

Peritoneal dialysis solution

1. • parenteral solution

Indications

Care involving peritoneal dialysis

1. Iodine

Section

Vitamins and minerals

1. • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
   • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
   • Oral > Solid: 190 mg

Indications

Iodine deficiency

Antiseptics

Therapeutic equivalent to povidone iodine for Povidone iodine

1. Iohexol

Section

Diagnostic agents > Radiocontrast media

1. • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

Indications

X-ray contrast media, iodinated

1. Ipecacuanha

Section

Antidotes and other substances used in poisonings > Non-specific

1. • Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

Indications

Unspecified injury, poisoning or certain other consequences of external causes

1. Ipratropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Respiratory > Inhalation > aerosol: 20 µg per dose

Indications

Chronic obstructive pulmonary disease Asthma

1. Irinotecan

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site

1. Isoflurane

Section

General anaesthetics and oxygen > Inhalational medicines

1. • Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

1. Isoniazid

Section

Antituberculosis medicines

1. • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
   • Parenteral > General injections > IV: 100 mg per mL

Indications

Tuberculosis Other specified tuberculosis

1. Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

1. • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)

Indications

Tuberculosis

1. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections

1. • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

1. Isoniazid + rifampicin

Section

Antituberculosis medicines

1. • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet

Indications

Tuberculosis

1. Isoniazid + rifapentine

Section

Antituberculosis medicines

1. • Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

1. Isoprenaline

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
   • Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

Indications

Bradycardia Cardiogenic shock

1. Isosorbide dinitrate

Section

Antianginal medicines

1. • Oral > Solid: 5 mg sublingual tablet

Indications

Angina pectoris

1. Itraconazole

Section

Antifungal medicines

1. • Oral > Liquid: 10 mg per mL
   • Oral > Solid: 100 mg

Indications

Chronic pulmonary aspergillosis Chromoblastomycosis Histoplasmosis Talaromycosis Sporotrichosis Paracoccidioidomycosis

1. Ivermectin

Section

Intestinal anthelminthics

1. • Oral > Solid: 3 mg tablet (scored)

Indications

Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis

Antifilarials

1. • Oral > Solid: 3 mg tablet (scored)

Onchocerciasis Lymphatic filariasis

Medicines for ectoparasitic infections

1. • Oral > Solid: 3 mg tablet (scored)

Scabies

1. Japanese encephalitis vaccine

Section

Recommendations for certain regions

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Kanamycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis

1. Kanamycin (injection)

Section

Antituberculosis medicines

1. • Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Ketamine

Section

General anaesthetics and oxygen > Injectable medicines

1. • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)

Indications

Anaesthetics and therapeutic gases

1. Lactulose

Section

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid

Indications

Palliative care

1. Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus

1. Lamivudine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

1. • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Lamotrigine

Section

Anticonvulsants/antiepileptics

1. • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

Indications

Epilepsy or seizures

1. Latanoprost

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

1. • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

Indications

Primary open-angle glaucoma

1. Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

1. Lenalidomide

Section

Immunomodulators

1. • Oral > Solid: 25 mg

Indications

Plasma cell myeloma

1. Leuprorelin

Section

Hormones and antihormones

1. • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast Malignant neoplasms of prostate

1. Levamisole

Section

Intestinal anthelminthics

1. • Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)

Indications

Ascariasis

1. Levodopa

Section

Antiparkinsonism medicines

1. • Oral > Solid: 250 mg

Indications

Parkinson disease

1. Levodopa + benserazide

Section

Antiparkinsonism medicines

Indications

Therapeutic equivalent to levodopa + carbidopa for Parkinson disease

1. Levodopa + carbidopa

Section

Antiparkinsonism medicines

1. • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

Indications

Parkinson disease

1. Levofloxacin

Section

Antituberculosis medicines

1. • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Levonorgestrel

Section

Oral hormonal contraceptives

1. • Oral > Solid: 30 µg
   • Oral > Solid: 750 µg [2]; 1.5 mg [1]

Indications

Contact with health services for contraceptive management Contact with health services for postcoital contraception

Intrauterine devices

1. • Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Contact with health services for insertion of contraceptive device

1. Levonorgestrel-releasing implant

Section

Implantable contraceptives

1. • Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

1. Levothyroxine

Section

Thyroid hormones and antithyroid medicines

1. • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications

Hypothyroidism

1. Lidocaine

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)

Indications

Ventricular tachyarrhythmia

Local anaesthetics

1. • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
   • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
   • Local > Topical > unspecified: 2 to 4% (hydrochloride)

Local anaesthetics

1. Lidocaine + epinephrine

Section

Local anaesthetics

1. • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
   • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

Indications

Local anaesthetics

1. Lindane

Section

Dermatological medicines (topical) > Scabicides and pediculicides

1. • Local > Topical > Cream: 1%
   • Local > Topical > Lotion: 1%

Indications

Scabies

1. Linezolid

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
   • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
   • Oral > Solid: 400 mg tablet; 600 mg tablet

Indications

Other specified bacterial diseases Methicillin resistant Staphylococcus aureus Vancomycin resistant Staphylococcus aureus Vancomycin resistant Enterococcus

Antituberculosis medicines

1. • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
   • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)

Multi-drug resistant Mycobacterium tuberculosis

1. Lisinopril + amlodipine

Section

Antihypertensive medicines

1. • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

Indications

Essential hypertension

1. Lisinopril + hydrochlorothiazide

Section

Antihypertensive medicines

1. • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

Indications

Essential hypertension

1. Lithium carbonate

Section

Medicines used in bipolar disorders

1. • Oral > Solid: 300 mg

Indications

Bipolar or related disorders

1. Long-acting insulin analogues

Section

Insulins

1. • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled syringe

Indications

Type 1 diabetes mellitus Type 2 diabetes mellitus

1. Loperamide

Section

Medicines for other common symptoms in palliative care

1. • Oral > Solid: 2 mg solid oral dosage form

Indications

Palliative care

1. Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Loratadine

Section

Antiallergics and medicines used in anaphylaxis

1. • Oral > Liquid: 1 mg per mL
   • Oral > Solid: 10 mg

Indications

Allergic or hypersensitivity conditions of unspecified type

1. Lorazepam

Section

Anticonvulsants/antiepileptics

1. • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule

Indications

Status epilepticus

1. Losartan

Section

Antihypertensive medicines

1. • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Indications

Essential hypertension

Medicines used in heart failure

1. • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet

Heart failure

1. Lovastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis

1. Lugol’s solution

Section

Thyroid hormones and antithyroid medicines

1. • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)

Indications

Thyrotoxicosis

1. Magnesium sulfate

Section

Anticonvulsants/antiepileptics

1. • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
   • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)

Indications

Severe pre-eclampsia Eclampsia

1. Mannitol

Section

Diuretics

1. • Parenteral > General injections > IV: 10% solution; 20% solution

Indications

Ocular hypertension Cerebral oedema

1. Measles vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against measles alone

1. Mebendazole

Section

Intestinal anthelminthics

1. • Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)

Indications

Ascariasis Enterobiasis Trichuriasis Hookworm diseases

Cysticidal medicines

1. • Oral > Solid: 500 mg tablet (chewable)

Other specified echinococcosis

1. Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

1. • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
   • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

Contact with health services for reasons associated with reproduction

Progestogens

1. • Oral > Solid: 5 mg

Excessive menstruation with irregular cycle

1. Mefloquine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 250 mg tablet (hydrochloride)

Indications

Malaria due to Plasmodium falciparum

Antimalarial medicines > For chemoprevention

1. • Oral > Solid: 250 mg tablet (hydrochloride)

Malaria due to Plasmodium falciparum

1. Meglumine antimoniate

Section

Antileishmaniasis medicines

1. • Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony

Indications

Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

1. Meglumine iotroxate

Section

Diagnostic agents > Radiocontrast media

1. • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL

Indications

X-ray contrast media, iodinated

1. Melarsoprol

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

1. • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

Indications

African trypanosomiasis

1. Melphalan

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg in vial powder for injection
   • Oral > Solid: 2 mg

Indications

Plasma cell myeloma

1. Meningococcal meningitis vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

1. Mercaptopurine

Section

Cytotoxic medicines

1. • Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities

1. Meropenem

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choice

Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis

Antituberculosis medicines

1. • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Multi-drug resistant Mycobacterium tuberculosis

1. Meropenem + vaborbactam

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem resistant Enterobacterales Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Acinetobacter baumannii

1. Mesalazine

Section

Anti-inflammatory medicines

Indications

Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis

1. Mesna

Section

Supportive medicines

1. • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
   • Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis

1. Metformin

Section

Oral hypoglycaemic agents

1. • Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

1. Methadone

Section

Medicines for disorders due to psychoactive substance use

1. • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Indications

Opioid dependence

Opioid analgesics

1. • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
   • Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

Chronic cancer pain

1. Methimazole

Section

Thyroid hormones and antithyroid medicines

1. • Oral > Solid: 5 mg; 10 mg; 20 mg

Indications

Thyrotoxicosis

1. Methionine

Section

Antidotes and other substances used in poisonings > Specific

1. • Oral > Solid: 250 mg (DL)

Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

1. Methotrexate

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
   • Oral > Solid: 2.5 mg (as sodium salt)

Indications

Malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 2.5 mg (as sodium salt)

Rheumatoid arthritis, serology unspecified

1. Methoxy polyethylene glycol-epoetin beta

Section

Antianaemia medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease

1. Methyldopa

Section

Antihypertensive medicines

1. • Oral > Solid: 250 mg

Indications

Essential hypertension Gestational hypertension

1. Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to ergometrine for Postpartum haemorrhage

1. Methylphenidate

Section

Medicines for mental and behavioural disorders

1. • Multiple formulations and strengths.

Indications

Attention deficit hyperactivity disorder

1. Methylprednisolone

Section

Hormones and antihormones

1. • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia

1. Methylthioninium chloride

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

Indications

Acquired methaemoglobinaemia

1. Metoclopramide

Section

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 5 mg per 5 mL
   • Oral > Solid: 10 mg (hydrochloride)
   • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Palliative care

Antiemetic medicines

1. • Oral > Liquid: 5 mg per 5 mL
   • Oral > Solid: 10 mg (hydrochloride)
   • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)

Nausea or vomiting

1. Metoprolol

Section

Antianginal medicines

Indications

Therapeutic equivalent to bisoprolol for Angina pectoris

Medicines used in heart failure

Therapeutic equivalent to bisoprolol for Heart failure

Antiarrhythmic medicines

Therapeutic equivalent to bisoprolol for Cardiac arrhythmia

Antihypertensive medicines

Therapeutic equivalent to bisoprolol for Essential hypertension

1. Metronidazole

Section

Access group antibiotics

1. • Oral > Liquid: 200 mg per 5 mL (as benzoate)
   • Oral > Solid: 200 to 500 mg tablet
   • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
   • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository

Indications

First choice

Trichomoniasis Intestinal infections due to Clostridioides difficile co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Necrotising fasciitis

Second choice

co-prescribed with ciprofloxacin Peritonitis (mild-moderate) co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate)

Other indications

Bacterial infection of unspecified site

Antiamoebic and antigiardiasis medicines

1. • Oral > Liquid: 200 mg per 5 mL (as benzoate)
   • Oral > Solid: 200 to 500 mg tablet
   • Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Amoebiasis

1. Micafungin

Section

Antifungal medicines

1. • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

Indications

Systemic or invasive candidosis

1. Miconazole

Section

Dermatological medicines (topical) > Antifungal medicines

1. • Local > Topical > Cream: 2% (nitrate)
   • Local > Topical > Ointment: 2% (nitrate)

Indications

Fungal infection of the skin

1. Midazolam

Section

Anticonvulsants/antiepileptics

1. • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration)
   • Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration

Indications

Status epilepticus Therapeutic equivalent to lorazepam for Status epilepticus

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 2 mg per mL oral liquid
   • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
   • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection

Palliative care

Preoperative medication and sedation for short-term procedures

1. • Parenteral > General injections > IV: 1 mg per mL
   • Oral > Liquid: 2 mg per mL
   • Oral > Solid: 15 mg tablet; 7.5 mg tablet

Sedative-hypnotic and anxiolytic drugs

1. Mifepristone – misoprostol

Section

Uterotonics

1. • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Induced abortion

1. Miltefosine

Section

Antileishmaniasis medicines

1. • Oral > Solid: 10 mg; 50 mg

Indications

Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

1. Misoprostol

Section

Uterotonics

1. • Oral > Solid: 200 µg
   • Local > Vaginal > tablet: 25 µg

Indications

Spontaneous abortion, incomplete, without complication Unspecified obstetric condition Postpartum haemorrhage

1. Mometasone

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide for Asthma

1. Mometasone + formoterol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to budesonide + formoterol for Asthma

1. Morphine

Section

Preoperative medication and sedation for short-term procedures

1. • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)

Indications

Opioids or related analgesics and agents affecting opioid receptors

Opioid analgesics

1. • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
   • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
   • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
   • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Pain

1. Moxifloxacin

Section

Antituberculosis medicines

1. • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
   • Oral > Solid: 400 mg tablet

Indications

Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

1. Multiple micronutrient powder

Section

Vitamins and minerals

1. • Oral > Other:

Indications

Iron deficiency anaemia

1. Multiple micronutrient supplement

Section

Other medicines administered to the mother

1. • Tablet containing:
   • Vit A: 800 mcg retinol activity equivalent
   • Vit C: 70 mg
   • Vit D: 5 mcg (200 IU)
   • Vit E: 10 mg alpha tocopherol equivalent
   • Vit B1: 1.4 mg
   • Vit B2: 1.4 mg
   • Vit B3: 18 mg niacin equivalent
   • Vit B6: 1.9 mg
   • Folic acid: 400 mcg
   • Vit B12: 2.6 mcg
   • Iron: 30 mg
   • Iodine: 150 mcg
   • Zinc: 15 mg
   • Selenium: 65 mcg
   • Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

1. Mumps vaccine

Section

Recommendations for immunization programmes with certain characteristics

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against mumps alone

1. Mupirocin

Section

Dermatological medicines (topical) > Anti-infective medicines

1. • Local > Topical > Cream: 2% (as mupirocin calcium)
   • Local > Topical > Ointment: 2%

Indications

Superficial bacterial folliculitis Impetigo

1. Nadroparin

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to enoxaparin for Venous thromboembolism Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease

1. Nalidixic acid

Section

Anti-infective medicines

1. • Oral > Solid: 250 mg; 500 mg

Indications

Shigella resistant to unspecified antibiotic

1. Naloxone

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)

Indications

Unintentional exposure to or harmful effects of opioids or related analgesics

1. Natamycin

Section

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Suspension: 5% eye drops

Indications

Infectious keratitis

1. Nelfinavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 250 mg (as mesilate)
   • Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Neostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Oral > Solid: 15 mg (neostigmine bromide)
   • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)

Indications

Myasthenia gravis Anticholinesterase reversible

1. Netilmicin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis

1. Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

1. • Oral > Liquid: 50 mg per 5 mL oral solution
   • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Niclosamide

Section

Intestinal anthelminthics

1. • Oral > Solid: 500 mg tablet (chewable)

Indications

Hymenolepiasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium

1. Nicotinamide

Section

Vitamins and minerals

1. • Oral > Solid: 50 mg

Indications

Pellagra

1. Nicotine replacement therapy

Section

Medicines for disorders due to psychoactive substance use

1. • Oral > Other: 2 mg chewing gum; 4 mg chewing gum
   • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour

Indications

Nicotine dependence

1. Nifedipine

Section

Antioxytocics (tocolytics)

1. • Oral > Solid: 10 mg (immediate-release)

Indications

Preterm labour without delivery

Antianginal medicines

1. • Oral > Solid: 10 mg

Angina pectoris

Antihypertensive medicines

1. • Oral > Solid: 10 mg tablet; sustained-release formulations

Essential hypertension

1. Nifurtimox

Section

Medicines for the treatment of 2nd stage African trypanosomiasis

1. • Oral > Solid: 120 mg

Indications

African trypanosomiasis

American trypanosomiasis

1. • Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet

Chagas disease

1. Nilotinib

Section

Targeted therapies

1. • Oral > Solid: 150 mg capsule; 200 mg capsule

Indications

Chronic myeloid leukaemia, not elsewhere classified

1. Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

1. Nitrofurantoin

Section

Access group antibiotics

1. • Oral > Liquid: 25 mg per 5 mL oral liquid
   • Oral > Solid: 100 mg tablet

Indications

First choice

Infectious cystitis

1. Nitrous oxide

Section

General anaesthetics and oxygen > Inhalational medicines

1. • Respiratory > Inhalation:

Indications

Anaesthetics and therapeutic gases

1. Nivolumab

Section

Immunomodulators

1. • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung Melanoma of skin Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung

1. Norethisterone

Section

Oral hormonal contraceptives

1. • Oral > Solid: 350 µg

Indications

Contact with health services for contraceptive management

Progestogens

1. • Oral > Solid: 5 mg

Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle

1. Norethisterone enantate

Section

Injectable hormonal contraceptives

1. • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

1. Normal immunoglobulin

Section

Human immunoglobulins

1. • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
   • Parenteral > General injections > IM: 16% protein solution
   • Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies Mucocutaneous lymph node syndrome

1. Nystatin

Section

Antifungal medicines

1. • Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL
   • Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet
   • Local > Topical > Other: 100000 IU pessary

Indications

Candidosis

1. Ocrelizumab

Section

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Indications

Relapsing-remitting multiple sclerosis

1. Ofloxacin

Section

Antituberculosis medicines

1. • Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Ear, nose and throat medicines [c]

Therapeutic equivalent to ciprofloxacin for Infectious diseases of external ear

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Solution (eye drops): 0.3%

Other specified conjunctivitis Infectious keratitis

1. Omadacycline

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
   • Oral > Solid: 300 mg

Indications

Methicillin resistant Staphylococcus aureus

1. Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

1. Omeprazole

Section

Antiulcer medicines

1. • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
   • Oral > Solid: 10 mg; 20 mg; 40 mg
   • Parenteral > General injections > IV: 40 mg in vial

Indications

Gastro-oesophageal reflux disease Peptic ulcer, site unspecified Gastrointestinal bleeding

1. Ondansetron

Section

Medicines for other common symptoms in palliative care

1. • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
   • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
   • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)

Indications

Palliative care

Antiemetic medicines

1. • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
   • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
   • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)

Nausea or vomiting

1. Oral rehydration salts

Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral

1. • Powder for dilution in 200 mL, 500 mL, 1 L:
   • – glucose 75 mEq
   • – sodium 75 mEq or mmol/L
   • – chloride 65 mEq or mmol/L
   • – potassium 20 mEq or mmol/L
   • – citrate 10 mmol/L
   • – osmolarity 245 mOsm/L
   • – glucose 13.5 g/L
   • – sodium chloride 2.6 g/L
   • – potassium chloride 1.5 g/L
   • – trisodium citrate dihydrate 2.9 g/L

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Oral rehydration

1. • Powder for dilution in 200 mL, 500 mL, 1 L:
   • – glucose 75 mEq
   • – sodium 75 mEq or mmol/L
   • – chloride 65 mEq or mmol/L
   • – potassium 20 mEq or mmol/L
   • – citrate 10 mmol/L
   • – osmolarity 245 mOsm/L
   • – glucose 13.5 g/L
   • – sodium chloride 2.6 g/L
   • – potassium chloride 1.5 g/L
   • – trisodium citrate dihydrate 2.9 g/L

Diarrhoea

1. Oral rehydration salts – zinc sulfate

Section

Medicines used in diarrhoea

1. • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)

Indications

Diarrhoea

1. Oseltamivir

Section

Other antivirals

1. • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

1. Osimertinib

Section

Targeted therapies

1. • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

1. Oxaliplatin

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

1. Oxamniquine

Section

Antischistosomals and other antitrematode medicines

1. • Oral > Liquid: 250 mg per 5 mL
   • Oral > Solid: 250 mg capsule

Indications

Schistosomiasis due to Schistosoma mansoni

1. Oxazolindinones

Section

Reserve group antibiotics

1. • .

Indications

Other specified bacterial diseases

1. Oxycodone

Section

Opioid analgesics

Indications

Therapeutic equivalent to morphine for Pain

1. Oxygen

Section

General anaesthetics and oxygen > Inhalational medicines

1. • Respiratory > Inhalation: (medical gas)

Indications

Anaesthetics and therapeutic gases

Medical gases

1. • Respiratory > Inhalation:

Respiratory failure as acute or chronic

1. Oxytetracycline

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Trachoma Therapeutic equivalent to tetracycline for Infectious blepharitis

1. Oxytocin

Section

Uterotonics

1. • Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

1. P-aminosalicylic acid

Section

Antituberculosis medicines

1. • Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Paclitaxel

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 6 mg per mL

Indications

Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

1. Palbociclib

Section

Targeted therapies

1. • Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

1. Paliperidone

Section

Medicines used in psychotic disorders

1. • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

Indications

Schizophrenia or other primary psychotic disorders

1. Palonosetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to ondansetron for Palliative care

Antiemetic medicines

Therapeutic equivalent to ondansetron for Nausea or vomiting

1. Pancreatic enzymes

Section

Pancreatic enzymes

1. • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.

Indications

Enzyme intestinal

1. Paracetamol

Section

Antimigraine medicines > For treatment of acute attack

1. • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
   • Oral > Solid: 300 to 500 mg

Indications

Migraine

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)

1. • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
   • Oral > Solid: 100 to 500 mg
   • Local > Rectal > Suppository: 100 mg

Pain

1. Paromomycin

Section

Antileishmaniasis medicines

1. • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

Indications

Visceral leishmaniasis

Antiamoebic and antigiardiasis medicines

1. • Oral > Liquid: 125 mg per 5 mL as sulfate
   • Oral > Solid: 250 mg as sulfate

Amoebiasis

1. Paroxetine

Section

Medicines used in depressive disorders

Indications

Therapeutic equivalent to fluoxetine for Depressive disorders

1. Pegaspargase

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 3750 units per 5 mL in vial

Indications

Lymphoid leukaemia, not elsewhere classified

1. Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

1. • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

1. Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

1. • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

1. Pembrolizumab

Section

Immunomodulators

1. • Parenteral > General injections > IV: 50 mg powder for injection

Indications

Therapeutic equivalent to nivolumab for Melanoma of skin Other specified malignant neoplasms of bronchus or lung

1. Penicillamine

Section

Antidotes and other substances used in poisonings > Specific

1. • Oral > Solid: 250 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 250 mg

Rheumatoid arthritis, serology unspecified

1. Pentamidine

Section

Medicines for the treatment of 1st stage African trypanosomiasis

1. • Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection

Indications

African trypanosomiasis

Antileishmaniasis medicines

1. • Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)

Visceral leishmaniasis

Antipneumocystosis and antitoxoplasmosis medicines

1. • Oral > Solid: 200 mg tablet; 300 mg tablet

Pneumocystosis

1. Permethrin

Section

Dermatological medicines (topical) > Scabicides and pediculicides

1. • Local > Topical > Lotion: 1%
   • Local > Topical > Cream: 5%

Indications

Pediculosis corporis Pediculosis capitis Scabies

1. Pertussis vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against pertussis alone

1. Pertuzumab

Section

Targeted therapies

1. • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

1. Phenobarbital

Section

Anticonvulsants/antiepileptics

1. • Oral > Liquid: 15 mg per 5 mL
   • Oral > Solid: 15 to 100 mg
   • Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium)

Indications

Epilepsy or seizures Status epilepticus

1. Phenoxymethylpenicillin

Section

Access group antibiotics

1. • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
   • Oral > Solid: 250 mg (as potassium salt) tablet
   • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

First choice

Acute pharyngitis Periapical abscess without sinus Bacterial pneumonia (Community-acquired pneumonia – mild to moderate)

Other indications

Bacterial infection of unspecified site

1. Phenytoin

Section

Anticonvulsants/antiepileptics

1. • Oral > Liquid: 25 to 30 mg per 5 mL
   • Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet
   • Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt)

Indications

Epilepsy or seizures

1. Phytomenadione

Section

Medicines affecting coagulation

1. • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
   • Oral > Solid: 10 mg tablet

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants Haemorrhagic or haematological disorders of fetus or newborn

1. Pilocarpine

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

1. • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

Indications

Primary open-angle glaucoma Acute angle closure with pupillary block Ocular hypertension

1. Piperacillin + tazobactam

Section

Watch group antibiotics

1. • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

First choice

Peritoneal abscess (severe) Neutropenia (high-risk) Peritonitis (severe) Other specified pneumonia (Hospital-acquired pneumonia)

Access group antibiotics

1. • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

First choice

co-prescribed with clindamycin Necrotising fasciitis

1. Platelets

Section

Blood and blood components

1. • Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

1. Plazomicin

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)

Indications

Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa Carbapenem resistant Enterobacterales

1. Pneumococcal vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against single bacterial diseases

1. Podophyllotoxin

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts

1. Podophyllum resin

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Solution: 10 to 25%

Indications

Plantar warts Anogenital warts

1. Poliomyelitis vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against poliomyelitis

1. Polygeline

Section

Plasma substitutes

1. • Parenteral > General injections > IV: 3.5% injectable solution
   • Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to dextran 70 for Hypovolaemia Hypovolaemia

1. Polymyxin B (injection)

Section

Reserve group antibiotics

1. • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection

Indications

Carbapenem resistant Enterobacterales Carbapenem resistant Acinetobacter baumannii Carbapenem-resistant Pseudomonas aeruginosa

1. Polymyxins

Section

Reserve group antibiotics

1. • .

Indications

Other specified bacterial diseases

1. Potassium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral

1. • Oral > Liquid: powder for solution

Indications

Hypokalaemia

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)

Hypokalaemia

1. Potassium ferric hexacyanoferrate

Section

Antidotes and other substances used in poisonings > Specific

1. • Oral > Solid: Powder for oral administration

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Potassium iodide

Section

Antifungal medicines

1. • Local > Topical > Solution: Saturated solution

Indications

Sporotrichosis

Thyroid hormones and antithyroid medicines

1. • Oral > Solid: 60 mg

Thyrotoxicosis

1. Potassium permanganate

Section

Dermatological medicines (topical) > Anti-infective medicines

1. • Local > Topical > Solution: aqueous solution: 1:10 000

Indications

Tropical phagedaenic ulcer Pemphigus Other specified pyogenic bacterial infection of skin and subcutaneous tissue Impetigo

1. Povidone iodine

Section

Antiseptics

1. • Local > Topical > Solution: 10% (equivalent to 1% available iodine)

Indications

Povidone iodine

1. Pralidoxime

Section

Antidotes and other substances used in poisonings > Specific

1. • .

Indications

Exposure to or harmful effects of undetermined intent of pesticides

1. Pramipexole

Section

Antiparkinsonism medicines

1. • Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

Indications

Parkinson disease

1. Pravastatin

Section

Lipid-lowering agents

Indications

Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis

1. Praziquantel

Section

Intestinal anthelminthics

1. • Oral > Solid: 600 mg tablet
   • Oral > Solid: 600 mg tablet; 150 mg tablet

Indications

Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium Hymenolepiasis

Antischistosomals and other antitrematode medicines

1. • Oral > Solid: 600 mg tablet

Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis

Cysticidal medicines

1. • Oral > Solid: 600 mg tablet; 500 mg tablet

Cysticercosis of central nervous system

1. Precipitated sulfur

Section

Dermatological medicines (topical) > Scabicides and pediculicides

1. • Local > Topical > Ointment:

Indications

Therapeutic equivalent to benzyl benzoate for Pthiriasis Therapeutic equivalent to benzyl benzoate for Pediculosis corporis Therapeutic equivalent to benzyl benzoate for Pediculosis capitis Therapeutic equivalent to benzyl benzoate for Scabies

1. Prednisolone

Section

Hormones and antihormones

1. • Oral > Liquid: 5 mg per mL
   • Oral > Solid: 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Plasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Malignant neoplasms of prostate

Anti-inflammatory medicines

1. • Local > Rectal > Retention enema:
   • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

Therapeutic equivalent to hydrocortisone for Crohn disease site Crohn disease site Ulcerative colitis

Antiallergics and medicines used in anaphylaxis

1. • Oral > Liquid: 5 mg per mL
   • Oral > Solid: 5 mg; 25 mg

Allergic or hypersensitivity conditions of unspecified type

Ophthalmological preparations > Anti-inflammatory agents

1. • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

Scleritis Anterior uveitis

1. Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Burkitt lymphoma including Burkitt leukaemia Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate

Antiallergics and medicines used in anaphylaxis

Therapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type

1. Primaquine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

Indications

Malaria due to Plasmodium ovale Malaria due to Plasmodium vivax

1. Probenecid

Section

Medicines used to treat gout

1. • Oral > Solid: 500 mg

Indications

Gout

1. Procainamide

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)
   • Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

Indications

Cardiac arrhythmia

1. Procaine benzylpenicillin

Section

Access group antibiotics

1. • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

First choice

Congenital syphilis [children]

Second choice

Syphilis

1. Procarbazine

Section

Cytotoxic medicines

1. • Oral > Solid: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma

1. Progesterone vaginal ring

Section

Intravaginal contraceptives

1. • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

1. Proguanil

Section

Antimalarial medicines > For chemoprevention

1. • Oral > Solid: 100 mg tablet (hydrochloride)

Indications

Malaria due to Plasmodium falciparum

1. Promethazine

Section

Antiemetic medicines

1. • Oral > Liquid: 5 mg per 5 mL (hydrochloride)
   • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
   • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

Indications

Nausea or vomiting

1. Propanol

Section

Antiseptics

Indications

Therapeutic equivalent to ethanol for Denatured alcohol

1. Propofol

Section

General anaesthetics and oxygen > Injectable medicines

1. • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

Indications

Anaesthetics and therapeutic gases

1. Propranolol

Section

Antihypertensive medicines

1. • Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Indications

Essential hypertension

Antianginal medicines

1. • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
   • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Angina pectoris

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
   • Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Cardiac arrhythmia

Antimigraine medicines > For prophylaxis

1. • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)

Migraine

1. Propylthiouracil

Section

Thyroid hormones and antithyroid medicines

1. • Oral > Solid: 50 mg

Indications

Thyrotoxicosis

1. Prostaglandin E1

Section

Medicines administered to the neonate [c]

1. • Parenteral > General injections > IV: 0.5 mg per mL in alcohol

Indications

Other specified congenital anomaly of great arteries including arterial duct

1. Prostaglandin E2

Section

Medicines administered to the neonate [c]

1. • Parenteral > General injections > IV: 1 mg per mL

Indications

Therapeutic equivalent to prostaglandin E1 for Other specified congenital anomaly of great arteries including arterial duct Other specified congenital anomaly of great arteries including arterial duct

1. Protamine sulfate

Section

Medicines affecting coagulation

1. • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

1. Protionamide

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis

1. Pyrantel

Section

Intestinal anthelminthics

1. • Oral > Liquid: 50 mg per mL (as embonate or pamoate)
   • Oral > Solid: 250 mg chewable tablet (as embonate or pamoate)

Indications

Ascariasis Trichuriasis Hookworm diseases Enterobiasis

1. Pyrazinamide

Section

Antituberculosis medicines

1. • Oral > Liquid: 30 mg per mL
   • Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg

Indications

Tuberculosis

1. Pyridostigmine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
   • Oral > Solid: 60 mg (pyridostigmine bromide)

Indications

Myasthenia gravis

1. Pyridoxine

Section

Vitamins and minerals

1. • Oral > Solid: 25 mg (hydrochloride)

Indications

Other specified polyneuropathy Vitamin B6 deficiency Sideroblastic anaemia

1. Pyrimethamine

Section

Antipneumocystosis and antitoxoplasmosis medicines

1. • Oral > Solid: 25 mg

Indications

Toxoplasmosis

1. Quinidine

Section

Antiarrhythmic medicines

1. • Oral > Solid: 200 mg (sulfate)

Indications

Cardiac arrhythmia

1. Quinine

Section

Antimalarial medicines > For curative treatment

1. • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
   • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)

Indications

Malaria due to Plasmodium falciparum

1. Rabies vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rabies

1. Raltegravir

Section

Antiretrovirals > Integrase inhibitors

1. • Oral > Liquid: 100 mg granules for oral suspension
   • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Ranibizumab

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

1. • .

Indications

Retinal venous occlusions Diabetic macular oedema Degenerative high myopia Age related macular degeneration

1. Ranitidine

Section

Antiulcer medicines

1. • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
   • Oral > Solid: 150 mg (as hydrochloride)
   • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

Indications

Peptic ulcer, site unspecified Gastro-oesophageal reflux disease

1. Rasburicase

Section

Supportive medicines

1. • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution

Indications

Tumour lysis syndrome

1. Ready to use therapeutic food

Section

Solutions correcting water, electrolyte and acid–base disturbances

1. • Lipid-based paste for oral consumption.

Indications

Acute malnutrition in infants, children or adolescents

1. Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

1. • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

1. Red blood cells

Section

Blood and blood components

1. • Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

1. Retinol

Section

Vitamins and minerals

1. • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
   • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
   • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule

Indications

Vitamin A deficiency

1. Ribavirin

Section

Other antivirals

1. • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
   • Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Viral haemorrhagic fever, not elsewhere classified

Medicines for hepatitis C > Other antivirals for hepatitis C

1. • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
   • Oral > Solid: 200 mg; 400 mg; 600 mg

Chronic hepatitis C

1. Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

1. Riboflavin

Section

Vitamins and minerals

1. • Oral > Solid: 5 mg

Indications

Vitamin B2 deficiency

1. Rifabutin

Section

Antituberculosis medicines

1. • Oral > Solid: 150 mg

Indications

Tuberculosis

1. Rifampicin

Section

Antituberculosis medicines

1. • Oral > Liquid: 20 mg per mL
   • Oral > Solid: 150 mg; 300 mg
   • Parenteral > General injections > IV: 600 mg in vial powder for injection

Indications

Tuberculosis Other specified tuberculosis

Antileprosy medicines

1. • Oral > Solid: 150 mg; 300 mg

Leprosy

1. Rifapentine

Section

Antituberculosis medicines

1. • Oral > Solid: 150 mg tablet; 300 mg tablet

Indications

Tuberculosis Latent tuberculosis

1. Risperidone

Section

Medicines used in psychotic disorders

1. • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
   • Parenteral > General injections > IM:

Indications

Schizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders

1. Ritonavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Rituximab

Section

Targeted therapies

1. • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas

1. Rivaroxaban

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation

1. Ropinirole

Section

Antiparkinsonism medicines

1. • Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

Indications

Parkinson disease

1. Rotavirus vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Rubella vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against rubella alone

1. Salbutamol

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
   • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
   • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers

Indications

Chronic obstructive pulmonary disease Asthma

1. Salicylic acid

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Solution: 5%

Indications

Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

1. Saquinavir

Section

Antiretrovirals > Protease inhibitors

1. • Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Selenium sulfide

Section

Dermatological medicines (topical) > Antifungal medicines

1. • Local > Topical > Suspension: 2% detergent-based

Indications

Seborrhoeic dermatitis Pityriasis versicolor

1. Senna

Section

Medicines for other common symptoms in palliative care

1. • Oral > Liquid: 7.5 mg per 5 mL oral liquid

Indications

Palliative care

Laxatives

1. • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

Constipation

1. Sertraline

Section

Medicines used in depressive disorders

Indications

Therapeutic equivalent to fluoxetine for Depressive disorders

1. Silver diamine fluoride

Section

Dental preparations

1. • Local > Dental > Solution: 38% w/v

Indications

Dental caries

1. Silver nitrate

Section

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Solution (eye drops): 1%

Indications

Neonatal conjunctivitis or dacryocystitis

1. Silver sulfadiazine

Section

Dermatological medicines (topical) > Anti-infective medicines

1. • Local > Topical > Cream: 1%

Indications

Burns

1. Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 150 mg

Indications

Chronic hepatitis C

1. Simvastatin

Section

Lipid-lowering agents

1. • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Indications

Mixed hyperlipidaemia Coronary atherosclerosis

Medicines for endocrine disorders

1. • Oral > Solid: 20 mg

Polycystic ovary syndrome

1. Smallpox vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Snake antivenom

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • .

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Sodium calcium edetate

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Sodium chloride

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)

Indications

Other specified disorders of fluid, electrolyte or acid-base balance

1. Sodium hydrogen carbonate

Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

1. • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)

Indications

Acidosis

1. Sodium nitrite

Section

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Sodium nitroprusside

Section

Antihypertensive medicines

1. • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

Indications

Hypertensive crisis

1. Sodium stibogluconate

Section

Antileishmaniasis medicines

1. • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

Indications

Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

1. Sodium thiosulfate

Section

Dermatological medicines (topical) > Antifungal medicines

1. • Local > Topical > Solution: 15%

Indications

Pityriasis versicolor

Antidotes and other substances used in poisonings > Specific

1. • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 400 mg; 200 mg

Indications

Chronic hepatitis C

1. Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

1. • Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet

Indications

Chronic hepatitis C

1. Spectinomycin

Section

Access group antibiotics

1. • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choice

Gonococcal infection

Other indications

Bacterial infection of unspecified site

1. Spironolactone

Section

Medicines used in heart failure

1. • Oral > Solid: 25 mg

Indications

Heart failure

Diuretics

1. • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
   • Oral > Solid: 25 mg

Oedema Ascites

1. Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Liquid: 5 mg per 5 mL powder for oral solution
   • Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Streptokinase

Section

Thrombolytic medicines

1. • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection

Indications

Acute myocardial infarction

1. Streptomycin (injection)

Section

Antituberculosis medicines

1. • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

Multi-drug resistant Mycobacterium tuberculosis

1. Succimer

Section

Antidotes and other substances used in poisonings > Specific

1. • Oral > Solid: 100 mg

Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

1. Sulfacetamide

Section

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Ointment: 10% (sodium salt)

Indications

Other specified conjunctivitis

1. Sulfadiazine

Section

Antipneumocystosis and antitoxoplasmosis medicines

1. • Oral > Solid: 500 mg

Indications

Toxoplasmosis

1. Sulfadoxine + pyrimethamine

Section

Antimalarial medicines > For curative treatment

1. • Oral > Solid: 500 mg + 25 mg tablet

Indications

Malaria due to Plasmodium falciparum

Antimalarial medicines > For chemoprevention

1. • Oral > Solid: 500 mg + 25 mg tablet
   • Oral > Solid: 250 mg + 12.5 mg tablet

Malaria due to Plasmodium falciparum Malaria

1. Sulfamethoxazole + trimethoprim

Section

Access group antibiotics

1. • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
   • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
   • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Indications

First choice

Infectious cystitis

Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

Other indications

Bacterial infection of unspecified site

Antipneumocystosis and antitoxoplasmosis medicines

1. • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
   • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
   • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Pneumocystosis

1. Sulfasalazine

Section

Disease-modifying anti-rheumatic drugs (DMARDs)

1. • Oral > Solid: 500 mg

Indications

Rheumatoid arthritis, serology unspecified

Anti-inflammatory medicines

1. • Oral > Solid: 500 mg
   • Local > Rectal > Suppository: 500 mg
   • Local > Rectal > Retention enema:

Crohn disease site Ulcerative colitis

1. Sumatriptan

Section

Antimigraine medicines > For treatment of acute attack

1. • Oral > Solid: 50 mg

Indications

Migraine

1. Suramin sodium

Section

Antifilarials

1. • Parenteral > General injections > IV: 1 g in vial

Indications

Filariasis

Medicines for the treatment of 1st stage African trypanosomiasis

1. • Parenteral > General injections > IV: 1 g in vial

African trypanosomiasis

1. Surfactant

Section

Medicines administered to the neonate [c]

1. • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

1. Suxamethonium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial

Indications

Muscle relaxants

1. Tacalcitol

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to calcipotriol for Psoriasis of unspecified type

1. Tacrolimus

Section

Immunomodulators for non-malignant disease

1. • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
   • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
   • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

Failure or rejection of transplanted organs or tissues

1. Tamoxifen

Section

Hormones and antihormones

1. • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast Malignant neoplasms of breast

1. Telmisartan + amlodipine

Section

Antihypertensive medicines

1. • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg

Indications

Essential hypertension

1. Telmisartan + hydrochlorothiazide

Section

Antihypertensive medicines

1. • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg

Indications

Essential hypertension

1. Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 25 mg

Indications

Chronic hepatitis B

1. Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Chronic hepatitis B

1. Terbinafine

Section

Dermatological medicines (topical) > Antifungal medicines

1. • Local > Topical > Cream: 1% terbinafine hydrochloride
   • Local > Topical > Ointment: 1% terbinafine hydrochloride

Indications

Fungal infection of the skin

1. Terbutaline

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma

1. Terizidone

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis

1. Testosterone

Section

Androgens

1. • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

Testicular dysfunction or testosterone-related disorders

1. Tetanus antitoxin

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

1. • Parenteral > General injections > IM: 50000 IU in vial

Indications

Tetanus

1. Tetanus vaccine

Section

Recommendations for all immunization programmes

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against tetanus alone

1. Tetracaine

Section

Ophthalmological preparations > Local anaesthetics

1. • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)

Indications

Local anaesthetics

1. Tetracycline

Section

Access group antibiotics

1. • Oral > Solid: 250 mg (hydrochloride)

Indications

Bacterial infection of unspecified site

Ophthalmological preparations > Anti-infective agents

1. • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)

Neonatal conjunctivitis or dacryocystitis Other specified conjunctivitis Infectious keratitis Trachoma Infectious blepharitis

1. Thalidomide

Section

Immunomodulators

1. • Oral > Solid: 50 mg

Indications

Plasma cell myeloma

1. Thiamine

Section

Vitamins and minerals

1. • Oral > Solid: 50 mg (hydrochloride)

Indications

Vitamin B1 deficiency

1. Thiopental

Section

General anaesthetics and oxygen > Injectable medicines

Indications

Therapeutic equivalent to propofol for Anaesthetics and therapeutic gases

1. Tick-borne encephalitis vaccine

Section

Recommendations for certain regions

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against arthropod-borne viral encephalitis

1. Tigecycline

Section

Reserve group antibiotics

1. • Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

1. Timolol

Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

1. • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

Indications

Ocular hypertension Primary open-angle glaucoma

1. Tinidazole

Section

Antiamoebic and antigiardiasis medicines

Indications

Therapeutic equivalent to metronidazole for Amoebiasis

1. Tioguanine

Section

Cytotoxic medicines

1. • Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

1. Tiotropium bromide

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

1. • Respiratory > Inhalation > dry powder: 18 µg capsule
   • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation

Indications

Chronic obstructive pulmonary disease

1. Tislelizumab

Section

Immunomodulators

1. • Parenteral > General injections > IV: 100 mg per 10 mL

Indications

Malignant neoplasms of urinary tract Hodgkin lymphoma

1. Tobramycin

Section

Ophthalmological preparations > Anti-infective agents

Indications

Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis

1. Tocilizumab

Section

Juvenile joint diseases

1. • Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial
   • Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe

Indications

Juvenile systemic arthritis

1. Tolbutamide

Section

Oral hypoglycaemic agents

1. • Oral > Solid: 500 mg

Indications

Type 2 diabetes mellitus

1. Torasemide

Section

Medicines used in heart failure

Indications

Therapeutic equivalent to furosemide for Heart failure

Diuretics

Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema

1. Tramadol

Section

Opioid analgesics

1. • Oral > Liquid: 100 mg per mL (hydrochloride)
   • Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
   • Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride)

Indications

Chronic cancer pain

1. Trametinib

Section

Targeted therapies

1. • Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

1. Tranexamic acid

Section

Medicines affecting coagulation

1. • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Haemorrhage, not elsewhere classified

Other medicines administered to the mother

1. • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Postpartum haemorrhage

1. Trastuzumab

Section

Targeted therapies

1. • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

1. Trastuzumab emtansine

Section

Targeted therapies

1. • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

1. Triamcinolone acetonide

Section

Juvenile joint diseases

Indications

Therapeutic equivalent to triamcinolone hexacetonide for Juvenile idiopathic arthritis

1. Triamcinolone hexacetonide

Section

Juvenile joint diseases

1. • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in 2 mL vial; 20 mg per mL in 10 mL vial

Indications

Juvenile idiopathic arthritis

1. Triclabendazole

Section

Antischistosomals and other antitrematode medicines

1. • Oral > Solid: 250 mg tablet

Indications

Paragonimiasis Fascioliasis

1. Trihexyphenidyl

Section

Antiparkinsonism medicines

1. • Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Indications

Parkinson disease Therapeutic equivalent to biperiden for Parkinson disease

1. Trimethoprim

Section

Access group antibiotics

1. • Oral > Liquid: 50 mg per mL
   • Oral > Solid: 100 mg; 200 mg

Indications

First choice

Infectious cystitis

1. Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate

1. Tropicamide

Section

Diagnostic agents > Ophthalmic medicines

1. • Local > Ophthalmological > Solution (eye drops): 0.5%

Indications

Cycloplegic drug

1. Tropisetron

Section

Medicines for other common symptoms in palliative care

Indications

Therapeutic equivalent to ondansetron for Palliative care

Antiemetic medicines

Therapeutic equivalent to ondansetron for Nausea or vomiting

1. Tuberculin, purified protein derivative

Section

Immunologicals > Diagnostic agents

1. • Parenteral > Locoregional injections > Intradermal:

Indications

Mycobacterial diseases

1. Tubocurarine

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

Indications

Muscle relaxants

1. Typhoid vaccine

Section

Recommendations for some high-risk populations

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against typhoid-paratyphoid alone

1. Ulipristal

Section

Oral hormonal contraceptives

1. • Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception

1. Umeclidinium

Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Indications

Therapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease

1. Urea

Section

Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation

1. • Local > Topical > Cream: 10%; 5%
   • Local > Topical > Ointment: 10%; 5%

Indications

Xerosis cutis or asteatosis

1. Valaciclovir

Section

Antiherpes medicines

Indications

Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella Therapeutic equivalent to aciclovir for Herpes simplex infections

1. Valganciclovir

Section

Other antivirals

1. • Oral > Liquid: 50 mg per mL powder for oral solution
   • Oral > Solid: 450 mg Tablet

Indications

Cytomegaloviral retinitis

1. Valproic acid (sodium valproate)

Section

Anticonvulsants/antiepileptics

1. • Oral > Liquid: 200 mg per 5 mL
   • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
   • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Indications

Epilepsy or seizures Status epilepticus

Medicines used in bipolar disorders

1. • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

Bipolar or related disorders

1. Vancomycin

Section

Watch group antibiotics

1. • Oral > Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
   • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
   • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

First choice

Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis

Second choice

Neutropenia (high-risk) Intestinal infections due to Clostridioides difficile

Other indications

Methicillin resistant Staphylococcus aureus

1. Varenicline

Section

Medicines for disorders due to psychoactive substance use

1. • Oral > Solid: 0.5 mg; 1 mg

Indications

Nicotine dependence

1. Varicella vaccine

Section

Recommendations for immunization programmes with certain characteristics

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Vecuronium

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

1. • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

Indications

Muscle relaxants

1. Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for Other specified melanoma of skin

1. Verapamil

Section

Antiarrhythmic medicines

1. • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
   • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Indications

Supraventricular tachyarrhythmia

Antianginal medicines

1. • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

Angina pectoris

1. Vinblastine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
   • Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma

1. Vincristine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
   • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Kaposi sarcoma of unspecified primary site

1. Vinorelbine

Section

Cytotoxic medicines

1. • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
   • Oral > Solid: 20 mg; 30 mg; 80 mg

Indications

Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site

1. Voriconazole

Section

Antifungal medicines

1. • Parenteral > General injections > IV: 200 mg in vial powder for injection
   • Oral > Liquid: 40 mg per mL powder for oral liquid
   • Oral > Solid: 50 mg tablet; 200 mg tablet

Indications

Chronic pulmonary aspergillosis Invasive aspergillosis

1. Warfarin

Section

Medicines affecting coagulation

1. • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)

Indications

Other specified diseases of arteries or arterioles Cerebral ischaemic stroke due to embolic occlusion Venous thromboembolism Atrial fibrillation

1. Water for injection

Section

Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous

1. • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule

Indications

Unspecified appropriateness of dosing or administration without injury or harm

1. Whole blood

Section

Blood and blood components

1. • Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

1. Xylometazoline

Section

Ear, nose and throat medicines [c]

1. • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL

Indications

Nasal congestion

1. Yellow fever vaccine

Section

Recommendations for certain regions

1. • All vaccines should comply with the WHO requirements for biological substances.

Indications

Need for immunization against certain single viral diseases

1. Zanubrutinib

Section

Targeted therapies

1. • Oral > Solid: 80 mg

Indications

Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma

1. Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

1. • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
   • Oral > Liquid: 50 mg per 5 mL
   • Oral > Solid: 250 mg capsule; 300 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

1. Zinc sulfate

Section

Medicines for diarrhoea

1. • Oral > Solid: 20 mg

Indications

Diarrhoea

1. Zoledronic acid

Section

Supportive medicines

1. • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Cancer Medicine

1-Acute Flaccid Myelitis (AFM) 2

AIDS (HIV/AIDS)

3 Alphaviruses

4 Alzheimer’s Disease

5 Alzheimer’s Diseases (Spanish)

6 Arboviral Encephalitis

7 Arthritis

8 Asthma

9 Babesiois

10 Bacterial Vaginosis

11 Blue-green Algae

12 Cancer

13 Cancer – Bladder

14 Cancer – Breast

15 Cancer – Breast Exams and Mammograms

16 Cancer – Cervical

17 Cancer – Cervical (Spanish)

18 Cancer – Colon

19 Cancer – Colorectal

20 Cancer – Endometrial

21 Cancer – Endometrial (Spanish)

22 Cancer – Kidney

23 Cancer – Leukemia

24 Cancer – Liver

25 Cancer – Lung

26 Cancer – Multiple Myeloma

27 Cancer – Oral

28 Cancer – Ovarian

29 Cancer – Ovarian (Spanish)

30 Cancer – Pancreatic

31 Cancer – Skin

32 Cancer – Stomach

33 Cancer – Testicular 3

4 Cancer – Thyroid 35 Cancer – Uterus

36 Cancer – Uterus (Spanish)

37 Cancer and Your Environment

38 Carbapenem-Resistant Enterobacteriaceae (CRE) Infections

39 Carbon Monoxide Poisoning

40 Cardiovascular Disease

41 Celiac Disease

42 Chagas Disease

43 Chancroid

44 Chickenpox

45 Chlamydia

46 Chronic Fatigue Syndrome.

( API  ‘s ) Active Pharmaceutical Ingredients ( GENERIC’S )  API ‘s
Albuterol (Bronchodilator)
Alprazolam (Tranquilizer)
Ambroxol HCl (Expectorant)
Amiloride HCl (Diuretic)
Amiodarone HCl (Anti-arrhythmic)
Amphetamine Aspartate (CNS, ADHD)§
d-Amphetamine Saccharate (CNS, ADHD)§
Amphetamine Sulfate (CNS, ADHD)§
d-Amphetamine Sulfate (CNS, ADHD)§
Aripiprazole (Neuroleptic)
Benzoyl Peroxide (Keratolytic)
Bisacodyl (Laxative)
Bromazepam (Tranquilizer)
Brotizolam (Hypnotic)
Bupivacaine Base (Local anesthetic)
Bupivacaine HCl (Local anesthetic)
Buprenorphine HCI (Analgesic)§
Chlordiazepoxide Base (Tranquilizer)
Chlordiazepoxide HCl (Tranquilizer)
Chlormadinone Acetate (Progestogen anti-neoplastic)
Chlorothiazide (Diuretic)
Cinacalcet (Antiparathyroid products)
Clobazam (Anxiolytic, anti-convulsant)
Clonazepam (Anti-epileptic)
Clorazepate Dipotassium (Anti-depressant)
Clozapine (Neuroleptic)
Cromolyn Sodium (Anti-allergic)
Diazepam (Tranquilizer)
Diltiazem HCl (Coronary vasodilator)
Dronedarone HCl (Anti-arrhythmic)
Eletriptan (Antimigraine triptan)
Emtricitabine (HIV anti-virals)
Epinephrine (Adrenergic agonist)
Epinephrine Tartrate (Adrenergic agonist)
Erythromycine Lactobionate (Anti-infective)
Estazolam (Hypnotic)
Etizolam (Anxiolytic)
Fentanyl (Analgesic)§
Fentanyl Citrate (Analgesic)§
Flunitrazepam (Hypnotic)
Flurazepam Dihydrochloride (Hypnotic)
Flurazepam HCl (Hypnotic)
Glipizide (Hypoglycemic)
Glyburide/Glibenclamide (Hypoglycemic)
Active Pharmaceutical Ingredients
Hydrochlorothiazide (Diuretic)
Hydrocodone Bitartrate Hydrate (Analgesic)§
Hydromorphone HCl (Analgesic)§
Labetalol HCl (Beta-adrenergic)
Levo Albuterol (Bronchodilator)
Lidocaine Base (Local anesthetic)
Lidocaine HCl (Local anesthetic)
Lorazepam (Anti-anxiety)
Lormetazepam (Hypnotic)
Medazepam (Tranquilizer)
Mesalamine/Mesalazine (Inflammatory bowel disease)
Metaproterenol Sulfate (Bronchodilator)
Midazolam Base (Hypnotic)
Midazolam HCl (Hypnotic)
Midazolam Maleate (Hypnotic)
Nicotine Polacrilex (Smoking cessation aid)
Nitroglycerine Solution (Cardiovasculars)
Norepinephrine Bitartrate (Sympathomimetic agent)
Ondansetron HCl (Anti-emetics)
Oxazepam (Tranquilizer)
Picosulfate Sodium (Laxative)
Potassium p-Aminobenzoate (Therapeutic agent
used in systemic antifibrosis treatment)
Prazepam (Anxiolytic, anticonvulsant)
Raloxifene HCl (Anti-osteoporotic)
Rivastigmine (Alzheimer disease)
Rivastigmine Hydrogen Tartrate (Alzheimer disease)
Salbutamol Sulfate (Bronchodilator)
Sotalol HCl (Beta-adrenoreceptor antagonists)
Sulfasalazine USP (Inflammatory bowel disease)
Temazepam (Tranquilizer)
Teprenone (Anti-ulcer)
Terbutaline Sulfate (Anti-asthmatic)
Terpin Hydrate (Expectorant)
Triazolam (Hypnotic)
Zolpidem Tartrate (Sedative/Hypnot

 

 

 

Devices

. Anesthesiology

. Critical Care Medicine

Cardiovascular & Thoracic Surgery

Diagnostic Radiology

Emergency Equipment’s

General Surgery

Orthopedic Surgery & Orthopedic

Physical Medicine and Rehabilitation (PM & R)

Plastic Surgery equipment